

SARS-CoV-2 501Y.V2 escapes neutralization by South A

Nature Medicine

27, 622-625

DOI: [10.1038/s41591-021-01285-x](https://doi.org/10.1038/s41591-021-01285-x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Genetic Variant of SARS-CoV-2: Would it matter for Controlling the Devastating Pandemic?. International Journal of Biological Sciences, 2021, 17, 1476-1485.	2.6	23
2	Key residues of the receptor binding domain in the spike protein of SARS-CoV-2 mediating the interactions with ACE2: a molecular dynamics study. Nanoscale, 2021, 13, 9364-9370.	2.8	22
3	Bioinformatic and MD Analysis of N501Y SARS-CoV-2 (UK) Variant. IFIP Advances in Information and Communication Technology, 2021, , 1-13.	0.5	1
5	OUP accepted manuscript. American Journal of Clinical Pathology, 2021, , .	0.4	7
6	Quantitative epitope analysis reveals drastic 63% reduced immuno-affinity and 60% enhanced transmissibility for SARS-CoV-2 variants. Nanoscale Advances, 2021, 3, 6903-6911.	2.2	2
7	More Than Just Gene Therapy Vectors: Lentiviral Vector Pseudotypes for Serological Investigation. Viruses, 2021, 13, 217.	1.5	13
8	Newly designed analogues from SARS-CoV inhibitors mimicking the druggable properties against SARS-CoV-2 and its novel variants. RSC Advances, 2021, 11, 31460-31476.	1.7	1
9	50 Years of structural immunology. Journal of Biological Chemistry, 2021, 296, 100745.	1.6	15
11	Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant. Emerging Microbes and Infections, 2021, 10, 1284-1292.	3.0	25
12	Molecular insights into the binding variance of the SARS-CoV-2 spike with human, cat and dog ACE2 proteins. Physical Chemistry Chemical Physics, 2021, 23, 13752-13759.	1.3	5
13	Rapidly emerging SARS-CoV-2 B.1.1.7 sub-lineage in the United States of America with spike protein D178H and membrane protein V70L mutations. Emerging Microbes and Infections, 2021, 10, 1293-1299.	3.0	18
14	A novel diagnostic test to screen SARS-CoV-2 variants containing E484K and N501Y mutations. Emerging Microbes and Infections, 2021, 10, 994-997.	3.0	15
15	COVID-19 vaccines: implementation, limitations and opportunities. Global Health & Medicine, 2021, 3, 1-5.	0.6	28
17	Molecular Epidemiology Surveillance of SARS-CoV-2: Mutations and Genetic Diversity One Year after Emerging. Pathogens, 2021, 10, 184.	1.2	29
18	SARS-CoV-2 Immuno-Pathogenesis and Potential for Diverse Vaccines and Therapies: Opportunities and Challenges. Infectious Disease Reports, 2021, 13, 102-125.	1.5	24
20	The challenge of emerging SARS-CoV-2 mutants to vaccine development. Journal of Genetics and Genomics, 2021, 48, 102-106.	1.7	19
21	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature, 2021, 592, 616-622.	13.7	1,232
29	Prolonged evolution of the human B cell response to SARS-CoV-2 infection. Science Immunology, 2021, 6, .	5.6	153

#	ARTICLE	IF	CITATIONS
31	Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1061-1063.	4.8	94
35	COVID-19: emergence and mutational diversification of SARS-CoV-2. <i>Microbial Biotechnology</i> , 2021, 14, 756-768.	2.0	17
39	Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. <i>Nature</i> , 2021, 593, 142-146.	13.7	574
41	Human Vaccines & Immunotherapeutics: news. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 618-619.	1.4	0
43	Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2. <i>Biology</i> , 2021, 10, 208.	1.3	16
45	Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications. <i>Viruses</i> , 2021, 13, 439.	1.5	107
48	Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. <i>Cell Host and Microbe</i> , 2021, 29, 463-476.e6.	5.1	1,054
49	Detection of a SARS-CoV-2 variant of concern in South Africa. <i>Nature</i> , 2021, 592, 438-443.	13.7	1,381
51	Immunity to SARS-CoV-2: Lessons Learned. <i>Frontiers in Immunology</i> , 2021, 12, 654165.	2.2	33
52	SARS-CoV-2 Variants of Concern in the United States—Challenges and Opportunities. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1037.	3.8	288
53	mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. <i>Science</i> , 2021, 372, 1413-1418.	6.0	468
56	SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations. <i>Viruses</i> , 2021, 13, 392.	1.5	92
57	CD8+ T-Cell Responses in COVID-19 Convalescent Individuals Target Conserved Epitopes From Multiple Prominent SARS-CoV-2 Circulating Variants. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab143.	0.4	83
60	Genomic Characterization of a Novel SARS-CoV-2 Lineage from Rio de Janeiro, Brazil. <i>Journal of Virology</i> , 2021, 95, .	1.5	302
61	Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19. <i>Vaccines</i> , 2021, 9, 243.	2.1	217
62	The envelope protein of SARS-CoV-2 increases intracellular Golgi pH and forms a cation channel that is regulated by pH. <i>Journal of Physiology</i> , 2021, 599, 2851-2868.	1.3	51
63	Profiles of current COVID-19 vaccines. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 271-283.	1.0	32
64	Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. <i>Nature Medicine</i> , 2021, 27, 917-924.	15.2	617

#	ARTICLE	IF	CITATIONS
65	The effect of spike mutations on SARS-CoV-2 neutralization. <i>Cell Reports</i> , 2021, 34, 108890.	2.9	200
68	Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. <i>BMJ, The</i> , 2021, 372, n579.	3.0	648
69	Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. <i>Nature</i> , 2021, 593, 130-135.	13.7	1,904
70	Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection. <i>Lancet, The</i> , 2021, 397, 1263-1264.	6.3	49
74	COVID vaccine efficacy against the B.1.351 (‘‘South African’’) variant—The urgent need to lay the groundwork for possible future challenge studies. <i>Human Vaccines and Immunotherapeutics</i> , 2021, , 1-2.	1.4	5
77	Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein. <i>PLoS ONE</i> , 2021, 16, e0250780.	1.1	66
78	SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation. <i>ELife</i> , 2021, 10, .	2.8	160
79	SARS-CoV-2 within-host diversity and transmission. <i>Science</i> , 2021, 372, .	6.0	278
82	Dynamic Management of Lung Cancer Care During Surging COVID-19. <i>Frontiers in Surgery</i> , 2021, 8, 663364.	0.6	7
83	Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. <i>Nature Reviews Immunology</i> , 2021, 21, 395-404.	10.6	223
84	Emergence and Spread of SARS-CoV-2 Lineages B.1.1.7 and P.1 in Italy. <i>Viruses</i> , 2021, 13, 794.	1.5	32
85	Neutralizing Antibody Therapeutics for COVID-19. <i>Viruses</i> , 2021, 13, 628.	1.5	99
86	Co-dominant neutralizing epitopes make anti-measles immunity resistant to viral evolution. <i>Cell Reports Medicine</i> , 2021, 2, 100257.	3.3	8
87	Age, Disease Severity and Ethnicity Influence Humoral Responses in a Multi-Ethnic COVID-19 Cohort. <i>Viruses</i> , 2021, 13, 786.	1.5	20
89	SARS-CoV-2 evolution and vaccines: cause for concern?. <i>Lancet Respiratory Medicine,the</i> , 2021, 9, 333-335.	5.2	161
90	Deep Mutational Scanning of Viral Glycoproteins and Their Host Receptors. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 636660.	1.6	12
92	Versatile and flexible microfluidic qPCR test for high-throughput SARS-CoV-2 and cellular response detection in nasopharyngeal swab samples. <i>PLoS ONE</i> , 2021, 16, e0243333.	1.1	14
93	Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques. <i>JCI Insight</i> , 2021, 6, .	2.3	52

#	ARTICLE	IF	CITATIONS
94	COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations. <i>Frontiers in Immunology</i> , 2021, 12, 669339.	2.2	81
96	SARS-CoV-2 protein subunit vaccination of mice and rhesus macaques elicits potent and durable neutralizing antibody responses. <i>Cell Reports Medicine</i> , 2021, 2, 100252.	3.3	33
97	Resurgence of SARS-CoV-2: Detection by community viral surveillance. <i>Science</i> , 2021, 372, 990-995.	6.0	91
98	The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study. <i>Lancet, The</i> , 2021, 397, 1265-1275.	6.3	282
99	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. <i>Cell</i> , 2021, 184, 2332-2347.e16.	13.5	784
100	SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. <i>Cell Host and Microbe</i> , 2021, 29, 529-539.e3.	5.1	324
102	Dissemination and evolution of SARS-CoV-2 in the early pandemic phase in South America. <i>Journal of Medical Virology</i> , 2021, 93, 4496-4507.	2.5	5
103	A human coronavirus evolves antigenically to escape antibody immunity. <i>PLoS Pathogens</i> , 2021, 17, e1009453.	2.1	183
104	Insights into SARS-CoV-2's Mutations for Evading Human Antibodies: Sacrifice and Survival. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2820-2826.	2.9	49
107	Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. <i>Cell</i> , 2021, 184, 2372-2383.e9.	13.5	1,166
109	Structural impact on SARS-CoV-2 spike protein by D614G substitution. <i>Science</i> , 2021, 372, 525-530.	6.0	344
110	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1351-1362.	6.3	540
112	Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines. <i>ACS Central Science</i> , 2021, 7, 757-767.	5.3	46
113	Temporal Dominance of B.1.1.7 over B.1.354 SARS-CoV-2 Variant: A Hypothesis Based on Areas of Variant Co-Circulation. <i>Life</i> , 2021, 11, 375.	1.1	9
114	SARS-CoV-2 one year on: evidence for ongoing viral adaptation. <i>Journal of General Virology</i> , 2021, 102, .	1.3	137
116	Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies: Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations. <i>Biochemistry</i> , 2021, 60, 1459-1484.	1.2	62
118	Intermolecular Interaction Analyses on SARS-CoV-2 Spike Protein Receptor Binding Domain and Human Angiotensin-Converting Enzyme 2 Receptor-Blocking Antibody/Peptide Using Fragment Molecular Orbital Calculation. <i>Journal of Physical Chemistry Letters</i> , 2021, 12, 4059-4066.	2.1	22
119	Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. <i>Cell Host and Microbe</i> , 2021, 29, 516-521.e3.	5.1	199

#	ARTICLE	IF	CITATIONS
120	Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. <i>Science</i> , 2021, 372, 815-821.	6.0	1,125
123	<scp>ACE2-based</scp> decoy receptors for <scp>SARS</scp> coronavirus 2. <i>Proteins: Structure, Function and Bioinformatics</i> , 2021, 89, 1065-1078.	1.5	23
127	Structural Analysis of the Novel Variants of SARS-CoV-2 and Forecasting in North America. <i>Viruses</i> , 2021, 13, 930.	1.5	13
129	Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. <i>Nature</i> , 2021, 594, 553-559.	13.7	199
130	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 818-823.	6.0	309
131	Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant. <i>New England Journal of Medicine</i> , 2021, 384, 1899-1909.	13.9	541
134	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. <i>Cell Host and Microbe</i> , 2021, 29, 806-818.e6.	5.1	49
135	Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection. <i>Journal of Infectious Diseases</i> , 2021, 224, 595-605.	1.9	20
140	Multifactorial Traits of SARS-CoV-2 Cell Entry Related to Diverse Host Proteases and Proteins. <i>Biomolecules and Therapeutics</i> , 2021, 29, 249-262.	1.1	2
142	SARS-CoV-2 variants: Subversion of antibody response and predicted impact on T cell recognition. <i>Cell Reports Medicine</i> , 2021, 2, 100286.	3.3	18
146	Identification of evolutionarily stable functional and immunogenic sites across the SARS-CoV-2 proteome and greater coronavirus family. <i>Bioinformatics</i> , 2021, 37, 4033-4040.	1.8	6
147	New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection. <i>Pharmaceuticals</i> , 2021, 14, 503.	1.7	6
148	Prediction and Evolution of the Molecular Fitness of SARS-CoV-2 Variants: Introducing SpikePro. <i>Viruses</i> , 2021, 13, 935.	1.5	22
149	New SARS-CoV-2 Variants – Clinical, Public Health, and Vaccine Implications. <i>New England Journal of Medicine</i> , 2021, 384, 1866-1868.	13.9	581
150	Problems associated with antiviral drugs and vaccines development for COVID-19: approach to intervention using expression vectors via GPI anchor. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2021, 40, 665-706.	0.4	12
151	Practical guidance for clinical laboratories for SARS-CoV-2 serology testing. <i>Canada Communicable Disease Report</i> , 2021, 47, 171-183.	0.6	12
152	SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 314-338.	6.6	75
153	Prioritisation of Compounds for 3CLpro Inhibitor Development on SARS-CoV-2 Variants. <i>Molecules</i> , 2021, 26, 3003.	1.7	23

#	ARTICLE	IF	CITATIONS
154	Severe acute respiratory syndrome coronavirus 2: Mutations and variants of concern – the Indian scenario. <i>International Journal of Molecular and Immuno Oncology</i> , 0, 6, 66-71.	0.0	4
155	siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses. <i>Molecular Pharmaceutics</i> , 2021, 18, 2105-2121.	2.3	34
156	Computational <i>Ab Initio</i> Interaction Analyses between Neutralizing Antibody and SARS-CoV-2 Variant Spike Proteins Using the Fragment Molecular Orbital Method. <i>Bulletin of the Chemical Society of Japan</i> , 2021, 94, 1794-1798.	2.0	4
157	Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2. <i>ACS Infectious Diseases</i> , 2021, 7, 1519-1534.	1.8	77
158	Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. <i>Cell Research</i> , 2021, 31, 732-741.	5.7	124
160	SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies. <i>Nature Medicine</i> , 2021, 27, 759-761.	15.2	65
161	SARS-CoV-2 worldwide replication drives rapid rise and selection of mutations across the viral genome: a time-course study – potential challenge for vaccines and therapies. <i>EMBO Molecular Medicine</i> , 2021, 13, e14062.	3.3	28
163	SARS-CoV-2: One Year in the Pandemic. What Have We Learned, the New Vaccine Era and the Threat of SARS-CoV-2 Variants. <i>Biomedicines</i> , 2021, 9, 611.	1.4	10
164	Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay. <i>Frontiers in Immunology</i> , 2021, 12, 688436.	2.2	26
165	Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. <i>New England Journal of Medicine</i> , 2021, 384, 1885-1898.	13.9	1,077
167	Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID-19 vaccines in Europe. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 72-82.	2.7	11
168	Altered Local Interactions and Long-Range Communications in UK Variant (B.1.1.7) Spike Glycoprotein. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5464.	1.8	9
170	Importation, circulation, and emergence of variants of SARS-CoV-2 in the South Indian state of Karnataka. <i>Wellcome Open Research</i> , 2021, 6, 110.	0.9	14
171	A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS-CoV-2 variants and wild-type of the virus. <i>MedComm</i> , 2021, 2, 430-441.	3.1	37
172	Efficacy and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>Vaccines</i> , 2021, 9, 467.	2.1	228
173	Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center. <i>Clinical Infectious Diseases</i> , 2022, 74, 821-828.	2.9	47
174	Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis. <i>Molecules and Cells</i> , 2021, 44, 392-400.	1.0	22
175	Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain. <i>Nature Communications</i> , 2021, 12, 3815.	5.8	44

#	ARTICLE	IF	CITATIONS
176	Protective efficacy of Ad26.COVS against SARS-CoV-2 B.1.351 in macaques. <i>Nature</i> , 2021, 596, 423-427.	13.7	40
177	Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). <i>New England Journal of Medicine</i> , 2021, 384, 2161-2163.	13.9	111
178	Macrophage biomimetic nanocarriers for anti-inflammation and targeted antiviral treatment in COVID-19. <i>Journal of Nanobiotechnology</i> , 2021, 19, 173.	4.2	45
179	Up State of the SARS-COV-2 Spike Homotrimer Favors an Increased Virulence for New Variants. <i>Frontiers in Medical Technology</i> , 2021, 3, 694347.	1.3	22
181	Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers. <i>Nature Communications</i> , 2021, 12, 3661.	5.8	48
182	Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	198
184	In vitro Characterization of Fitness and Convalescent Antibody Neutralization of SARS-CoV-2 Cluster 5 Variant Emerging in Mink at Danish Farms. <i>Frontiers in Microbiology</i> , 2021, 12, 698944.	1.5	40
186	Role of SARS-CoV-2 and ACE2 variations in COVID-19. <i>Biomedical Journal</i> , 2021, 44, 235-244.	1.4	20
187	Longitudinal Antibody Dynamics Against Structural Proteins of SARS-CoV-2 in Three COVID-19 Patients Shows Concurrent Development of IgA, IgM, and IgG. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 2497-2506.	1.6	9
188	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. <i>Microorganisms</i> , 2021, 9, 1389.	1.6	4
189	SARS-CoV-2 variants, spike mutations and immune escape. <i>Nature Reviews Microbiology</i> , 2021, 19, 409-424.	13.6	2,650
191	Safety and Efficacy of Single-Dose Ad26.COVS Vaccine against Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 2187-2201.	13.9	1,954
192	An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants. <i>Scientific Reports</i> , 2021, 11, 12740.	1.6	54
194	Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?. <i>Viruses</i> , 2021, 13, 1192.	1.5	150
195	Field performance evaluation of the PanBio rapid SARS-CoV-2 antigen assay in an epidemic driven by the B.1.351 variant in the Eastern Cape, South Africa. <i>Journal of Clinical Virology Plus</i> , 2021, 1, 100013.	0.4	20
196	Smartphone screen testing, a novel pre-diagnostic method to identify SARS-CoV-2 infectious individuals. <i>ELife</i> , 2021, 10, .	2.8	9
197	Acceptance of COVID-19 Vaccine among the Healthcare Workers in the Eastern Cape, South Africa: A Cross Sectional Study. <i>Vaccines</i> , 2021, 9, 666.	2.1	51
198	Immunogenicity of Ad26.COVS vaccine against SARS-CoV-2 variants in humans. <i>Nature</i> , 2021, 596, 268-272.	13.7	290

#	ARTICLE	IF	CITATIONS
200	Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. <i>Immunity</i> , 2021, 54, 1276-1289.e6.	6.6	112
201	An Overview of the Epidemiologic, Diagnostic and Treatment Approaches of COVID-19: What do We Know?. <i>Public Health Reviews</i> , 2021, 42, 1604061.	1.3	6
205	Novel Highly Divergent SARS-CoV-2 Lineage With the Spike Substitutions L249S and E484K. <i>Frontiers in Medicine</i> , 2021, 8, 697605.	1.2	6
206	Multi-Subunit SARS-CoV-2 Vaccine Design Using Evolutionarily Conserved T- and B- Cell Epitopes. <i>Vaccines</i> , 2021, 9, 702.	2.1	5
207	Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. <i>Science</i> , 2021, 373, .	6.0	318
208	Detection of R.1 lineage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with spike protein W152L/E484K/G769V mutations in Japan. <i>PLoS Pathogens</i> , 2021, 17, e1009619.	2.1	40
209	Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 642-648.	6.0	211
210	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. <i>Nature</i> , 2021, 596, 103-108.	13.7	222
212	CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 4048.	5.8	45
213	Inhibitory effect on SARS-CoV-2 infection of neferine by blocking Ca ²⁺ -dependent membrane fusion. <i>Journal of Medical Virology</i> , 2021, 93, 5825-5832.	2.5	20
214	SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies. <i>Viruses</i> , 2021, 13, 1211.	1.5	35
215	Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes. <i>MBio</i> , 2021, 12, e0069621.	1.8	61
216	SARS-CoV-2 variants of concern: the knowns and unknowns. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2021, 40, 100868.	0.6	5
220	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Sequence Characteristics of Coronavirus Disease 2019 (COVID-19) Persistence and Reinfection. <i>Clinical Infectious Diseases</i> , 2022, 74, 237-245.	2.9	59
221	Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Host Displaying Treatment Induced Viral Evolution. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab295.	0.4	22
226	Dynamic Profiling of Binding and Allosteric Propensities of the SARS-CoV-2 Spike Protein with Different Classes of Antibodies: Mutational and Perturbation-Based Scanning Reveals the Allosteric Duality of Functionally Adaptable Hotspots. <i>Journal of Chemical Theory and Computation</i> , 2021, 17, 4578-4598.	2.3	39
227	Tackling COVID-19 with neutralizing monoclonal antibodies. <i>Cell</i> , 2021, 184, 3086-3108.	13.5	309
228	Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. <i>Nature</i> , 2021, 595, 718-723.	13.7	128

#	ARTICLE	IF	CITATIONS
229	Live Virus Neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 Variants following INO-4800 Vaccination of Ferrets. <i>Frontiers in Immunology</i> , 2021, 12, 694857.	2.2	9
230	COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era. <i>Molecular Biotechnology</i> , 2021, 63, 885-897.	1.3	8
233	COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 3991.	5.8	241
234	B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. <i>Cell</i> , 2021, 184, 3205-3221.e24.	13.5	73
235	Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 226.	7.1	103
236	COVID-19 and SARS-CoV-2 Variants: Current Challenges and Health Concern. <i>Frontiers in Genetics</i> , 2021, 12, 693916.	1.1	55
237	Fncas9-based CRISPR diagnostic for rapid and accurate detection of major SARS-CoV-2 variants on a paper strip. <i>ELife</i> , 2021, 10, .	2.8	53
238	Despite vaccination, China needs non-pharmaceutical interventions to prevent widespread outbreaks of COVID-19 in 2021. <i>Nature Human Behaviour</i> , 2021, 5, 1009-1020.	6.2	81
239	Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. <i>Cell</i> , 2021, 184, 3426-3437.e8.	13.5	424
240	Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 2370.	3.8	307
241	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. <i>Science</i> , 2021, 373, .	6.0	174
243	Human immunoglobulin from transchromosomal bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-10.	1.4	20
244	Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells. <i>Cells</i> , 2021, 10, 1761.	1.8	34
246	Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries. <i>Cell Discovery</i> , 2021, 7, 57.	3.1	28
247	SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. <i>Science</i> , 2021, 373, 648-654.	6.0	385
248	Neutralizing Antibody Responses After SARS-CoV-2 Infection in End-Stage Kidney Disease and Protection Against Reinfection. <i>Kidney International Reports</i> , 2021, 6, 1799-1809.	0.4	13
249	Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19?. <i>Stem Cell Research and Therapy</i> , 2021, 12, 425.	2.4	15
250	An Update on Severe Acute Respiratory Syndrome Coronavirus 2 Diversity in the US National Capital Region: Evolution of Novel and Variants of Concern. <i>Clinical Infectious Diseases</i> , 2022, 74, 1419-1428.	2.9	24

#	ARTICLE	IF	CITATIONS
251	An intranasal vaccine durably protects against SARS-CoV-2 variants in mice. <i>Cell Reports</i> , 2021, 36, 109452.	2.9	90
252	Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin. <i>Journal of Travel Medicine</i> , 2021, 28, .	1.4	94
254	Molecular definition of severe acute respiratory syndrome coronavirus 2 receptorâ€binding domain mutations: Receptor affinity versus neutralization of receptor interaction. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 143-149.	2.7	26
255	Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC:) Tj ETQq1 1 0.784314 rgBT /Overlo	2.1	94
258	Has translational genomics come of age in Africa?. <i>Human Molecular Genetics</i> , 2021, 30, R164-R173.	1.4	11
260	SARS-CoV-2 Mutations and their Viral Variants. <i>Cytokine and Growth Factor Reviews</i> , 2022, 63, 10-22.	3.2	113
261	Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains. <i>ELife</i> , 2021, 10, .	2.8	42
262	The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines. <i>Brazilian Journal of Infectious Diseases</i> , 2021, 25, 101606.	0.3	94
263	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. <i>Nature Communications</i> , 2021, 12, 4196.	5.8	332
264	HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens. <i>Cell Host and Microbe</i> , 2021, 29, 1093-1110.	5.1	73
265	Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ TÂcell reactivity in infected or vaccinated individuals. <i>Cell Reports Medicine</i> , 2021, 2, 100355.	3.3	490
266	Contemporary narrative review of treatment options for COVID â€19. <i>Respirology</i> , 2021, 26, 745-767.	1.3	12
267	Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy. <i>International Journal of Biological Macromolecules</i> , 2021, 183, 203-212.	3.6	28
268	Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19. <i>Cell Reports</i> , 2021, 36, 109385.	2.9	23
269	Hypothesis: Possible influence of antivector immunity and SARSâ€CoVâ€2 variants on efficacy of ChAdOx1 nCoVâ€19 vaccine. <i>British Journal of Pharmacology</i> , 2022, 179, 218-226.	2.7	11
271	Modification of the Spike Protein for Vaccines against Enveloped RNA Viruses. <i>Molecular Biology</i> , 2021, 55, 538-547.	0.4	2
272	Ongoing global and regional adaptive evolution of SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	196
273	The success of SARS-CoV-2 vaccines and challenges ahead. <i>Cell Host and Microbe</i> , 2021, 29, 1111-1123.	5.1	67

#	ARTICLE	IF	CITATIONS
274	Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. <i>Cell Reports</i> , 2021, 36, 109353.	2.9	95
275	A Possible Role of Remdesivir and Plasma Therapy in the Selective Sweep and Emergence of New SARS-CoV-2 Variants. <i>Journal of Clinical Medicine</i> , 2021, 10, 3276.	1.0	18
276	Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 1498.	1.5	33
277	Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative. <i>ACS Infectious Diseases</i> , 2021, 7, 2546-2564.	1.8	34
278	Inhalable nanocatchers for SARS-CoV-2 inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	34
279	COVID-19 transmission and the safety of air travel during the pandemic: a scoping review. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 415-422.	1.3	13
280	SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data. <i>Eurosurveillance</i> , 2021, 26, .	3.9	31
281	COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. <i>Biomolecules</i> , 2021, 11, 993.	1.8	136
282	Broad sarbecovirus neutralization by a human monoclonal antibody. <i>Nature</i> , 2021, 597, 103-108.	13.7	220
283	SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. <i>Cell</i> , 2021, 184, 3936-3948.e10.	13.5	241
285	hACE2 Fc-neutralization antibody cocktail provides synergistic protection against SARS-CoV-2 and its spike RBD variants. <i>Cell Discovery</i> , 2021, 7, 54.	3.1	10
286	Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 4210.	5.8	82
288	Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 4598.	5.8	88
289	Interpreting estimates of coronavirus disease 2019 (COVID-19) vaccine efficacy and effectiveness to inform simulation studies of vaccine impact: a systematic review. <i>Wellcome Open Research</i> , 0, 6, 185.	0.9	17
290	Beyond the new normal: Assessing the feasibility of vaccine-based suppression of SARS-CoV-2. <i>PLoS ONE</i> , 2021, 16, e0254734.	1.1	12
291	The Pathogenic Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Possible Mechanisms for Immune Evasion?. <i>Frontiers in Immunology</i> , 2021, 12, 693579.	2.2	2
292	Ultrapotent mini-proteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease. <i>Cell Host and Microbe</i> , 2021, 29, 1151-1161.e5.	5.1	36
294	Catching SARS-CoV-2 by Sequence Hybridization: a Comparative Analysis. <i>MSystems</i> , 2021, 6, e0039221.	1.7	11

#	ARTICLE	IF	CITATIONS
295	Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor. <i>Cell and Bioscience</i> , 2021, 11, 168.	2.1	69
296	Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals. <i>Cell Reports</i> , 2021, 36, 109604.	2.9	67
297	B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies. <i>MBio</i> , 2021, 12, e0138621.	1.8	52
299	An update on novel approaches for diagnosis and treatment of SARS-CoV-2 infection. <i>Cell and Bioscience</i> , 2021, 11, 164.	2.1	10
300	The association between mechanical ventilator compatible bed occupancy and mortality risk in intensive care patients with COVID-19: a national retrospective cohort study. <i>BMC Medicine</i> , 2021, 19, 213.	2.3	28
301	Structure-guided TÂcell vaccine design for SARS-CoV-2 variants and sarbecoviruses. <i>Cell</i> , 2021, 184, 4401-4413.e10.	13.5	65
302	Effect of time and titer in convalescent plasma therapy for COVID-19. <i>IScience</i> , 2021, 24, 102898.	1.9	16
303	Minimally instrumented SHERLOCK (miSHERLOCK) for CRISPR-based point-of-care diagnosis of SARS-CoV-2 and emerging variants. <i>Science Advances</i> , 2021, 7, .	4.7	189
304	Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes. <i>Nature Communications</i> , 2021, 12, 4676.	5.8	74
306	Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. <i>Nature Communications</i> , 2021, 12, 4886.	5.8	65
308	Probing the Increased Virulence of Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617 (Indian) Tj ETQq0 0 0 rgBT /Ovgrlock 10 T	0.2	3
309	Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 788-796.	2.8	40
310	Plant-produced SARS-CoV-2 receptor binding domain (RBD) variants showed differential binding efficiency with anti-spike specific monoclonal antibodies. <i>PLoS ONE</i> , 2021, 16, e0253574.	1.1	10
311	Crucial Mutations of Spike Protein on SARS-CoV-2 Evolved to Variant Strains Escaping Neutralization of Convalescent Plasmas and RBD-Specific Monoclonal Antibodies. <i>Frontiers in Immunology</i> , 2021, 12, 693775.	2.2	38
312	The impact of high-resolution structural data on stemming the COVID-19 pandemic. <i>Current Opinion in Virology</i> , 2021, 49, 127-138.	2.6	2
313	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 317.	7.1	68
316	SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the United Kingdom. <i>EClinicalMedicine</i> , 2021, 38, 101021.	3.2	24
317	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. <i>Immunity</i> , 2021, 54, 1853-1868.e7.	6.6	230

#	ARTICLE	IF	CITATIONS
318	Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. <i>Nature Reviews Immunology</i> , 2021, 21, 626-636.	10.6	777
319	Fisetin for COVID-19 in skilled nursing facilities: Senolytic trials in the COVID era. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 3023-3033.	1.3	35
320	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2021, 12, 5061.	5.8	150
321	A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site. <i>Immunity</i> , 2021, 54, 2385-2398.e10.	6.6	46
322	Neutralization of SARS-CoV-2 by highly potent, hyperthermostable, and mutation-tolerant nanobodies. <i>EMBO Journal</i> , 2021, 40, e107985.	3.5	69
323	Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection. <i>Cell Discovery</i> , 2021, 7, 71.	3.1	26
324	The rapid adaptation of SARS-CoV-2—rise of the variants: transmission and resistance. <i>Journal of Microbiology</i> , 2021, 59, 807-818.	1.3	18
326	The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal. <i>Exploration of Immunology</i> , 2021, , 199-225.	1.7	5
328	Mass spectrometry-based proteomics in basic and translational research of SARS-CoV-2 coronavirus and its emerging mutants. <i>Clinical Proteomics</i> , 2021, 18, 19.	1.1	12
329	Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo. <i>Cell Discovery</i> , 2021, 7, 65.	3.1	51
331	Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant. <i>Biochemical and Biophysical Research Communications</i> , 2021, 566, 135-140.	1.0	46
332	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. <i>Nature Immunology</i> , 2021, 22, 1306-1315.	7.0	57
333	Severe Acute Respiratory Syndrome Coronavirus-2 Inactivation Activity of the Polyphenol-Rich Tea Leaf Extract with Concentrated Theaflavins and Other Virucidal Catechins. <i>Molecules</i> , 2021, 26, 4803.	1.7	6
334	The Emergence and Spread of Novel SARS-CoV-2 Variants. <i>Frontiers in Public Health</i> , 2021, 9, 696664.	1.3	24
335	Potential SARS-CoV-2 vaccines: Concept, progress, and challenges. <i>International Immunopharmacology</i> , 2021, 97, 107622.	1.7	14
336	A novel nano therapeutic using convalescent plasma derived exosomal (CPExo) for COVID-19: A combined hyperactive immune modulation and diagnostics. <i>Chemico-Biological Interactions</i> , 2021, 344, 109497.	1.7	16
337	Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in Japan. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab430.	0.4	18
338	The ongoing evolution of variants of concern and interest of SARS-CoV-2 in Brazil revealed by convergent indels in the amino (N)-terminal domain of the spike protein. <i>Virus Evolution</i> , 2021, 7, veab069.	2.2	31

#	ARTICLE	IF	CITATIONS
339	Myxobacterial depsipeptide chondramides interrupt SARS-CoV-2 entry by targeting its broad, cell tropic spike protein. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 12209-12220.	2.0	10
340	A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. <i>Immunity</i> , 2021, 54, 2399-2416.e6.	6.6	79
341	Recombinant <i>Mycobacterium paragordoniae</i> Expressing SARS-CoV-2 Receptor-Binding Domain as a Vaccine Candidate Against SARS-CoV-2 Infections. <i>Frontiers in Immunology</i> , 2021, 12, 712274.	2.2	10
342	Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques. <i>Nature Communications</i> , 2021, 12, 5215.	5.8	22
343	Lectin from <i>Triticum vulgare</i> (WGA) Inhibits Infection with SARS-CoV-2 and Its Variants of Concern Alpha and Beta. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10205.	1.8	17
344	Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen. <i>Frontiers in Immunology</i> , 2021, 12, 707977.	2.2	21
345	Immunity elicited by natural infection or Ad26.COVS2.S vaccination protects hamsters against SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021, 13, eabj3789.	5.8	32
346	Genomic surveillance to combat COVID-19: challenges and opportunities. <i>Lancet Microbe</i> , The, 2021, 2, e481-e484.	3.4	122
347	A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model. <i>European Journal of Immunology</i> , 2022, 52, 770-783.	1.6	24
348	Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against reinfection with B.1.1.7 and B.1.351 variants. <i>Science Translational Medicine</i> , 2021, 13, eabj2641.	5.8	15
350	Tracking down B.1.351 SARS-CoV-2 variant in Pakistan through genomic surveillance. <i>Journal of Medical Virology</i> , 2022, 94, 32-34.	2.5	7
351	S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 S-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basis. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 343.	7.1	24
352	Fast SARS-CoV-2 Variant Detection Using Snapback Primer High-Resolution Melting. <i>Diagnostics</i> , 2021, 11, 1788.	1.3	8
353	Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study. <i>The Lancet Global Health</i> , 2021, 9, e1216-e1225.	2.9	131
356	Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. <i>Cell Reports Medicine</i> , 2021, 2, 100405.	3.3	110
357	A Novel Real-Time RT-PCR-Based Methodology for the Preliminary Typing of SARS-CoV-2 Variants, Employing Non-Extendable LNA Oligonucleotides and Three Signature Mutations at the Spike Protein Receptor-Binding Domain. <i>Life</i> , 2021, 11, 1015.	1.1	5
358	Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0052721.	1.8	71
359	Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021, 13, eabj5413.	5.8	79

#	ARTICLE	IF	CITATIONS
360	Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. <i>Science Translational Medicine</i> , 2021, 13, eabh2624.	5.8	155
361	Genetic drift in the genome of SARS-CoV-2 and its global health concern. <i>Journal of Medical Virology</i> , 2022, 94, 88-98.	2.5	17
362	Could live attenuated vaccines better control COVID-19?. <i>Vaccine</i> , 2021, 39, 5719-5726.	1.7	29
363	A Potential Role of the CD47/SIRPalpha Axis in COVID-19 Pathogenesis. <i>Current Issues in Molecular Biology</i> , 2021, 43, 1212-1225.	1.0	9
364	Genome interaction of the virus and the host genes and non-coding RNAs in SARS-CoV-2 infection. <i>Immunobiology</i> , 2021, 226, 152130.	0.8	10
366	An ultrapotent pan- β -coronavirus lineage B (β -CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. <i>Protein and Cell</i> , 2022, 13, 655-675.	4.8	25
369	Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction. <i>Journal of Biological Chemistry</i> , 2021, 297, 101202.	1.6	28
370	Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 1372-1377.	6.0	459
371	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. <i>Lancet HIV</i> , 2021, 8, e568-e580.	2.1	124
372	Antibody screening at reduced pH enables preferential selection of potentially neutralizing antibodies targeting SARS-CoV-2. <i>AIChE Journal</i> , 2021, 67, e17440.	1.8	4
373	Mass Spectrometry-based Proteomics and Glycoproteomics in COVID-19 Biomarkers Identification: A Mini-review. <i>Journal of Analysis and Testing</i> , 2021, 5, 298-313.	2.5	17
375	The "Delta Plus" COVID-19 variant has evolved to become the next potential variant of concern: mutation history and measures of prevention. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2022, 33, 109-112.	0.7	43
376	Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection. <i>Science Translational Medicine</i> , 2021, 13, eabj0847.	5.8	40
377	Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. <i>Nature Microbiology</i> , 2021, 6, 1233-1244.	5.9	237
378	Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. <i>Science Advances</i> , 2021, 7, eabj5365.	4.7	83
379	The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology. <i>Nature Medicine</i> , 2021, 27, 1518-1524.	15.2	178
380	Protocol for safe, affordable, and reproducible isolation and quantitation of SARS-CoV-2 RNA from wastewater. <i>PLoS ONE</i> , 2021, 16, e0257454.	1.1	16
381	Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 752003.	2.2	62

#	ARTICLE	IF	CITATIONS
384	E484K as an innovative phylogenetic event for viral evolution: Genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil. <i>Infection, Genetics and Evolution</i> , 2021, 93, 104941.	1.0	58
388	Understanding the molecular interaction of SARS-CoV-2 spike mutants with ACE2 (angiotensin) Tj ETQq1 1 0.784314 rgBT / Overlock 10	2.0	19
390	The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages. <i>Cell</i> , 2021, 184, 5189-5200.e7.	13.5	186
391	Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study. <i>Clinical Microbiology and Infection</i> , 2022, 28, 301.e1-301.e8.	2.8	28
392	The biological and clinical significance of emerging SARS-CoV-2 variants. <i>Nature Reviews Genetics</i> , 2021, 22, 757-773.	7.7	778
393	Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. <i>Biomedicines</i> , 2021, 9, 1303.	1.4	87
394	Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern. <i>IScience</i> , 2021, 24, 103006.	1.9	23
395	A bioluminescent and homogeneous SARS-CoV-2 spike RBD and hACE2 interaction assay for antiviral screening and monitoring patient neutralizing antibody levels. <i>Scientific Reports</i> , 2021, 11, 18428.	1.6	10
396	Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany. <i>Lancet Regional Health - Europe</i> , The, 2021, 8, 100164.	3.0	83
397	The Immune Response to SARS-CoV-2 and Variants of Concern. <i>Viruses</i> , 2021, 13, 1911.	1.5	18
398	Cytoplasmic Tail Truncation of SARS-CoV-2 Spike Protein Enhances Titer of Pseudotyped Vectors but Masks the Effect of the D614G Mutation. <i>Journal of Virology</i> , 2021, 95, e0096621.	1.5	17
400	Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19. <i>EBioMedicine</i> , 2021, 71, 103519.	2.7	13
401	Recent progress on the mutations of SARS-CoV-2 spike protein and suggestions for prevention and controlling of the pandemic. <i>Infection, Genetics and Evolution</i> , 2021, 93, 104971.	1.0	19
402	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , 2021, 184, 5432-5447.e16.	13.5	131
403	A look into the future of the COVID-19 pandemic in Europe: an expert consultation. <i>Lancet Regional Health - Europe</i> , The, 2021, 8, 100185.	3.0	72
404	COVID-19 vaccine candidates and vaccine development platforms available worldwide. <i>Journal of Pharmaceutical Analysis</i> , 2021, 11, 675-682.	2.4	8
405	Antibody Response against SARS-CoV-2 Infection: Implications for Diagnosis, Treatment and Vaccine Development. <i>International Reviews of Immunology</i> , 2022, 41, 393-413.	1.5	13
406	Vaccines efficacy to SARS-CoV-2 variants require holistic knowledge of viral immunology and protein biochemistry. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4128-4130.	1.4	1

#	ARTICLE	IF	CITATIONS
407	High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. <i>Nature</i> , 2021, 600, 512-516.	13.7	174
408	Impact of the Delta variant on vaccine efficacy and response strategies. <i>Expert Review of Vaccines</i> , 2021, 20, 1201-1209.	2.0	177
409	A one-step real-time RT-PCR assay for simultaneous typing of SARS-CoV-2 mutations associated with the E484K and N501Y spike protein amino-acid substitutions. <i>Journal of Virological Methods</i> , 2021, 296, 114242.	1.0	10
410	Temporal spread and evolution of SARS-CoV-2 in the second pandemic wave in Brazil. <i>Journal of Medical Virology</i> , 2022, 94, 926-936.	2.5	11
411	In silico study of some selective phytochemicals against a hypothetical SARS-CoV-2 spike RBD using molecular docking tools. <i>Computers in Biology and Medicine</i> , 2021, 137, 104818.	3.9	23
412	COVID-19, the first pandemic in the post-genomic era. <i>Current Opinion in Virology</i> , 2021, 50, 40-48.	2.6	40
413	Anti-SARS-CoV-2 and anti-cytokine storm neutralizing antibody therapies against COVID-19: Update, challenges, and perspectives. <i>International Immunopharmacology</i> , 2021, 99, 108036.	1.7	10
414	Investigating the possible origin and transmission routes of SARS-CoV-2 genomes and variants of concern in Bangladesh. <i>Infection, Genetics and Evolution</i> , 2021, 95, 105057.	1.0	2
415	Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2. <i>Infection, Genetics and Evolution</i> , 2021, 95, 105038.	1.0	110
416	Phylogenetic reconstruction of the initial stages of the spread of the SARS-CoV-2 virus in the Eurasian and American continents by analyzing genomic data. <i>Virus Research</i> , 2021, 305, 198551.	1.1	9
417	SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020–March 2021. <i>Emerging Infectious Diseases</i> , 2021, 27, 3020-3029.	2.0	78
418	E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies. <i>Journal of Molecular Graphics and Modelling</i> , 2021, 109, 108035.	1.3	52
419	Evolution of SARS-CoV-2: Review of Mutations, Role of the Host Immune System. <i>Nephron</i> , 2021, 145, 392-403.	0.9	58
420	Comparative Analysis of SARS-CoV-2-Specific B Cell and Humoral Responses Elicited by Sputnik V in Naïve and COVID-19-Recovered Vaccine Recipients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
421	Overview of approved and upcoming vaccines for SARS-CoV-2: a living review. <i>Oxford Open Immunology</i> , 2021, 2, iqab010.	1.2	18
423	Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy. <i>Emerging Microbes and Infections</i> , 2021, 10, 710-712.	3.0	7
424	Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination. <i>Emerging Microbes and Infections</i> , 2021, 10, 1390-1403.	3.0	16
425	Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. <i>Emerging Microbes and Infections</i> , 2021, 10, 507-535.	3.0	202

#	ARTICLE	IF	CITATIONS
429	A year of genomic surveillance reveals how the SARS-CoV-2 pandemic unfolded in Africa. <i>Science</i> , 2021, 374, 423-431.	6.0	144
431	Thermodynamics and kinetics in antibody resistance of the 501Y.V2 SARS-CoV-2 variant. <i>RSC Advances</i> , 2021, 11, 33438-33446.	1.7	3
432	SARS-CoV-2 Variants of Concern. <i>Yonsei Medical Journal</i> , 2021, 62, 961.	0.9	183
433	Divergence of Delta and Beta Variants and SARS-CoV-2 Evolved in Advanced HIV Disease into Two Serological Phenotypes. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
434	A comprehensive review of the analysis and integration of omics data for SARS-CoV-2 and COVID-19. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	9
435	Comprehensive serological strategy for the diagnosis and monitoring of SARS-CoV-2. From infection to vaccine control. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 44-45.	0.5	0
436	INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2021, 6, 121.	2.9	36
437	HIV status alters disease severity and immune cell responses in Beta variant SARS-CoV-2 infection wave. <i>ELife</i> , 2021, 10, .	2.8	28
438	Immune memory from SARS-CoV-2 infection in hamsters provides variant-independent protection but still allows virus transmission. <i>Science Immunology</i> , 2021, 6, eabm3131.	5.6	37
439	Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera. <i>IScience</i> , 2021, 24, 103341.	1.9	47
440	Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 202-221.	2.8	569
441	The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2673-2675.	4.8	25
442	Significantly reduced abilities to cross-neutralize SARS-CoV-2 variants by sera from convalescent COVID-19 patients infected by Delta or early strains. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2560-2562.	4.8	11
443	Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. <i>Nature Microbiology</i> , 2021, 6, 1433-1442.	5.9	94
444	The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization. <i>Molecular Biology Reports</i> , 2022, 49, 647-656.	1.0	11
445	Assessing Multiplex Tiling PCR Sequencing Approaches for Detecting Genomic Variants of SARS-CoV-2 in Municipal Wastewater. <i>MSystems</i> , 2021, 6, e0106821.	1.7	26
446	Mechanisms of SARS-CoV-2 entry into cells. <i>Nature Reviews Molecular Cell Biology</i> , 2022, 23, 3-20.	16.1	1,532
447	The global epidemic of SARS-CoV-2 variants and their mutational immune escape. <i>Journal of Medical Virology</i> , 2022, 94, 847-857.	2.5	80

#	ARTICLE	IF	CITATIONS
448	Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects. <i>Journal of Virology</i> , 2022, 96, JVI0111021.	1.5	29
449	Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. <i>Vaccines</i> , 2021, 9, 1195.	2.1	90
450	Engineering Extracellular Vesicles Enriched with Palmitoylated ACE2 as COVID-19 Therapy. <i>Advanced Materials</i> , 2021, 33, e2103471.	11.1	60
451	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. <i>Science</i> , 2021, 374, 1343-1353.	6.0	83
452	Beta RBD boost broadens antibody-mediated protection against SARS-CoV-2 variants in animal models. <i>Cell Reports Medicine</i> , 2021, 2, 100450.	3.3	17
453	Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 720357.	1.8	7
454	Weak Cross-Lineage Neutralization by Anti SARS-CoV-2 Spike Antibodies after Natural Infection or Vaccination Is Rescued by Repeated Immunological Stimulation. <i>Vaccines</i> , 2021, 9, 1124.	2.1	3
455	Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV. <i>Nature Communications</i> , 2021, 12, 5839.	5.8	67
456	Rapid and Successful Implementation of a COVID-19 Convalescent Plasma Programme—The South African Experience. <i>Viruses</i> , 2021, 13, 2050.	1.5	5
458	COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. <i>Nature Communications</i> , 2021, 12, 6097.	5.8	38
459	Systemic and mucosal immune profiling in asymptomatic and symptomatic SARS-CoV-2-infected individuals reveal unlinked immune signatures. <i>Science Advances</i> , 2021, 7, eabi6533.	4.7	16
462	Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 6103.	5.8	117
463	SARS-CoV-2 UK, South African and Brazilian Variants in Karachi- Pakistan. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 724208.	1.6	1
464	Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern. <i>Cell Discovery</i> , 2021, 7, 96.	3.1	21
465	Prior infection with SARS-CoV-2 boosts and broadens Ad26.COVS immunogenicity in a variant-dependent manner. <i>Cell Host and Microbe</i> , 2021, 29, 1611-1619.e5.	5.1	106
466	Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada. <i>Cmaj</i> , 2021, 193, E1619-E1625.	0.9	220
467	Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants. <i>Science Advances</i> , 2021, 7, eabj3107.	4.7	23
470	A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge. <i>Npj Vaccines</i> , 2021, 6, 129.	2.9	47

#	ARTICLE	IF	CITATIONS
471	SARS-CoV-2 beta variant substitutions alter spike glycoprotein receptor binding domain structure and stability. <i>Journal of Biological Chemistry</i> , 2021, 297, 101371.	1.6	6
473	Engineered Ribosyl-1-Kinase Enables Concise Synthesis of Molnupiravir, an Antiviral for COVID-19. <i>ACS Central Science</i> , 2021, 7, 1980-1985.	5.3	91
474	High Individual Heterogeneity of Neutralizing Activities against the Original Strain and Nine Different Variants of SARS-CoV-2. <i>Viruses</i> , 2021, 13, 2177.	1.5	21
475	RT-qPCR assays for SARS-CoV-2 variants of concern in wastewater reveals compromised vaccination-induced immunity. <i>Water Research</i> , 2021, 207, 117808.	5.3	39
476	SARS-CoV-2 surveillance in Italy through phylogenomic inferences based on Hamming distances derived from pan-SNPs, -MNP and -InDels. <i>BMC Genomics</i> , 2021, 22, 782.	1.2	12
477	SARS-CoV-2 immunity and an overview of the COVID-19 vaccines. <i>Medicinski Podmladak</i> , 2021, 72, 20-29.	0.2	3
478	Getting out of crises: Environmental, social-ecological and evolutionary research is needed to avoid future risks of pandemics. <i>Environment International</i> , 2022, 158, 106915.	4.8	18
479	SARS-CoV-2 Mutations and Variants: what do we know so far?. <i>Microbes, Infection and Chemotherapy</i> , 0, 1, e1256.	0.0	5
480	A review of epidemiology, clinical features and disease course, transmission dynamics, and neutralization efficacy of SARS-CoV-2 variants. <i>Egyptian Journal of Bronchology</i> , 2021, 15, .	0.3	4
481	Probing Affinity, Avidity, Anticooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses. <i>ACS Central Science</i> , 2021, 7, 1863-1873.	5.3	20
482	Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant. <i>Scientific Reports</i> , 2021, 11, 21849.	1.6	26
483	Cross-reactivity of antibodies from non-hospitalized COVID-19 positive individuals against the native, B.1.351, B.1.617.2, and P.1 SARS-CoV-2 spike proteins. <i>Scientific Reports</i> , 2021, 11, 21601.	1.6	20
484	SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence. <i>Epidemiology and Infection</i> , 2021, 149, 1-24.	1.0	43
485	Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model. <i>EBioMedicine</i> , 2021, 73, 103675.	2.7	26
487	Syrian hamsters as a model of lung injury with SARS-CoV-2 infection: Pathologic, physiologic, and detailed molecular profiling. <i>Translational Research</i> , 2022, 240, 1-16.	2.2	33
488	Assessment of the COVID-19 epidemiological situation in St. Petersburg. <i>Zhurnal Mikrobiologii i Epidemiologii i Immunobiologii</i> , 2021, 98, 497-511.	0.3	14
489	Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants. <i>Nature Communications</i> , 2021, 12, 6304.	5.8	42
490	Performance Evaluation of Lateral Flow Assays for Coronavirus Disease-19 Serology. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 31-56.	0.7	8

#	ARTICLE	IF	CITATIONS
491	Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape. <i>Frontiers in Immunology</i> , 2021, 12, 744242.	2.2	44
492	Genomic surveillance reveals the detection of SARS-CoV-2 delta, beta, and gamma VOCs during the third wave in Pakistan. <i>Journal of Medical Virology</i> , 2022, 94, 1115-1129.	2.5	21
494	Coronavirus Disease Update on Epidemiology, Virology, and Prevention. <i>Compendium of Continuing Education in Dentistry (Jamesburg, NJ: 1995)</i> , 2021, 42, 280-289.	0.1	0
495	Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2. <i>Theranostics</i> , 2022, 12, 1-17.	4.6	6
496	Update of the epidemiological distribution of COVID-19 variants: a review article. <i>Revista Da Associação Médica Brasileira</i> , 2021, 67, 1368-1371.	0.3	1
497	D614G mutation and SARS-CoV-2: impact on S-protein structure, function, infectivity, and immunity. <i>Applied Microbiology and Biotechnology</i> , 2021, 105, 9035-9045.	1.7	34
498	A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection. <i>Npj Vaccines</i> , 2021, 6, 143.	2.9	47
499	Production and Characterization of Nucleocapsid and RBD Cocktail Antigens of SARS-CoV-2 in <i>Nicotiana benthamiana</i> Plant as a Vaccine Candidate against COVID-19. <i>Vaccines</i> , 2021, 9, 1337.	2.1	28
500	Effective Prophylaxis of COVID-19 in Rhesus Macaques Using a Combination of Two Parenterally-Administered SARS-CoV-2 Neutralizing Antibodies. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 753444.	1.8	13
501	Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine. <i>Nature</i> , 2022, 601, 410-414.	13.7	71
502	Identification of a therapeutic interfering particle—A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance. <i>Cell</i> , 2021, 184, 6022-6036.e18.	13.5	36
503	Evolution of the SARS-CoV-2 genome and emergence of variants of concern. <i>Archives of Virology</i> , 2022, 167, 293-305.	0.9	28
504	N501Y and K417N Mutations in the Spike Protein of SARS-CoV-2 Alter the Interactions with Both hACE2 and Human-Derived Antibody: A Free Energy of Perturbation Retrospective Study. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 6079-6084.	2.5	74
505	SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12114.	1.8	22
506	Immune response against SARS-CoV-2 variants: the role of neutralization assays. <i>Npj Vaccines</i> , 2021, 6, 142.	2.9	26
507	The Role of Serology Testing in the Context of Immunization Policies for COVID-19 in Latin American Countries. <i>Viruses</i> , 2021, 13, 2391.	1.5	11
509	Fighting SARS-CoV-2 with green seaweed <i>Ulva</i> sp. extract: extraction protocol predetermines crude ulvan extract anti-SARS-CoV-2 inhibition properties in <i>in vitro</i> Vero-E6 cells assay. <i>PeerJ</i> , 2021, 9, e12398.	0.9	8
510	XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants. <i>Frontiers in Immunology</i> , 2021, 12, 761250.	2.2	7

#	ARTICLE	IF	CITATIONS
511	Improved SARS-CoV-2 Spike Glycoproteins for Pseudotyping Lentiviral Vectors. <i>Frontiers in Virology</i> , 2021, 1, .	0.7	1
512	T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naïve UK health-care workers: a multicentre prospective cohort study. <i>Lancet Microbe</i> , The, 2022, 3, e21-e31.	3.4	131
513	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. <i>Seminars in Immunology</i> , 2021, 55, 101533.	2.7	72
514	Debulking SARS-CoV-2 in saliva using angiotensin converting enzyme 2 in chewing gum to decrease oral virus transmission and infection. <i>Molecular Therapy</i> , 2022, 30, 1966-1978.	3.7	39
515	Nanoparticulate CpG-adjuvanted SARS-CoV-2 S1 protein elicits broadly neutralizing and Th1-biased immunoreactivity in mice. <i>International Journal of Biological Macromolecules</i> , 2021, 193, 1885-1897.	3.6	12
516	SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021. <i>Microbiology Spectrum</i> , 2021, 9, e0109621.	1.2	39
518	Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor- α inhibitors. <i>Med</i> , 2021, 2, 1327-1341.e4.	2.2	31
519	CRISPR-Cas12a-Based Detection for the Major SARS-CoV-2 Variants of Concern. <i>Microbiology Spectrum</i> , 2021, 9, e0101721.	1.2	40
520	COVID-19 Infection Among Women in Iran Exposed vs Unexposed to Children Who Received Attenuated Poliovirus Used in Oral Polio Vaccine. <i>JAMA Network Open</i> , 2021, 4, e2135044.	2.8	18
521	Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021. <i>Infection, Genetics and Evolution</i> , 2022, 97, 105164.	1.0	9
522	SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021. <i>BMC Medicine</i> , 2021, 19, 303.	2.3	45
523	Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape. <i>Cell</i> , 2021, 184, 6229-6242.e18.	13.5	72
524	Evolutionary and Phenotypic Characterization of Two Spike Mutations in European Lineage 20E of SARS-CoV-2. <i>MBio</i> , 2021, 12, e0231521.	1.8	6
525	SNP and Phylogenetic Characterization of Low Viral Load SARS-CoV-2 Specimens by Target Enrichment. <i>Frontiers in Virology</i> , 2021, 1, .	0.7	6
526	Regulatory challenges of convalescent plasma collection during the evolving stages of COVID-19 pandemic in the United States. <i>Transfusion</i> , 2022, 62, 483-492.	0.8	2
527	Genomic evidence of SARS-CoV-2 reinfection in the Republic of Korea. <i>Journal of Medical Virology</i> , 2022, 94, 1717-1722.	2.5	2
528	Public health implications of SARS-CoV-2 variants of concern: a rapid scoping review. <i>BMJ Open</i> , 2021, 11, e055781.	0.8	22
529	SARS CoV-2 Delta variant exhibits enhanced infectivity and a minor decrease in neutralization sensitivity to convalescent or post-vaccination sera. <i>IScience</i> , 2021, 24, 103467.	1.9	26

#	ARTICLE	IF	CITATIONS
530	Rapid test to assess the escape of SARS-CoV-2 variants of concern. <i>Science Advances</i> , 2021, 7, eabl7682.	4.7	21
531	Validation of a Saliva-Based Test for the Molecular Diagnosis of SARS-CoV-2 Infection. <i>Disease Markers</i> , 2022, 2022, 1-8.	0.6	10
532	Optimization of Single-Dose VSV-Based COVID-19 Vaccination in Hamsters. <i>Frontiers in Immunology</i> , 2021, 12, 788235.	2.2	11
533	Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112527.	2.5	34
534	A comprehensive overview of identified mutations in SARS CoV-2 spike glycoprotein among Iranian patients. <i>Gene</i> , 2022, 813, 146113.	1.0	8
535	Transmission cluster of COVID-19 cases from Uruguay: emergence and spreading of a novel SARS-CoV-2 ORF6 deletion. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2022, 116, e210275.	0.8	5
536	Predictive Profiling of SARS-CoV-2 Variants by Deep Mutational Learning. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
538	Insights on the mutational landscape of the SARS-CoV-2 Omicron variant receptor-binding domain. <i>Cell Reports Medicine</i> , 2022, 3, 100527.	3.3	47
539	Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, 816220.	2.2	22
540	Computational construction of a glycoprotein multi-epitope subunit vaccine candidate for old and new South-African SARS-CoV-2 virus strains. <i>Informatics in Medicine Unlocked</i> , 2022, 28, 100845.	1.9	8
541	A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo. <i>Nature Communications</i> , 2022, 13, 155.	5.8	49
543	Structure-guided design of multi-epitopes vaccine against variants of concern (VOCs) of SARS-CoV-2 and validation through In silico cloning and immune simulations. <i>Computers in Biology and Medicine</i> , 2022, 140, 105122.	3.9	4
544	Innovative vaccine approaches—a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2022, 1511, 59-86.	1.8	5
545	DNA Based Vaccine Expressing SARS-CoV-2 Spike-CD40L Fusion Protein Confers Protection Against Challenge in a Syrian Hamster Model. <i>Frontiers in Immunology</i> , 2021, 12, 785349.	2.2	7
546	SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity. <i>Cell Reports Medicine</i> , 2022, 3, 100510.	3.3	51
547	The Emergence of the Omicron (B.1.1.529) SARS-CoV-2 Variant: What is the Impact on the Continued Pandemic?. <i>Journal of Epidemiology and Global Health</i> , 2022, 12, 143-146.	1.1	27
548	Resolution of viral load in mild COVID-19 patients is associated with both innate and adaptive immune responses. <i>Journal of Clinical Virology</i> , 2022, 146, 105060.	1.6	14
549	mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. <i>Immunity</i> , 2022, 55, 355-365.e4.	6.6	76

#	ARTICLE	IF	CITATIONS
550	Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model. <i>Vaccine</i> , 2022, 40, 1289-1298.	1.7	9
551	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339.	7.1	9
552	SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses. <i>Cell</i> , 2022, 185, 872-880.e3.	13.5	165
553	The ins and outs of SARS-CoV-2 variants of concern (VOCs). <i>Archives of Virology</i> , 2022, 167, 327-344.	0.9	35
554	SARS-CoV-2 Variants, Vaccines, and Host Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 809244.	2.2	176
555	From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines. <i>Nano-Micro Letters</i> , 2022, 14, 41.	14.4	26
557	Convalescent plasma therapy against the emerging SARS-CoV-2 variants: Delineation of the potentialities and risks. <i>International Journal of Surgery</i> , 2022, 97, 106204.	1.1	17
560	Ex Vivo and in Vivo suppression of SARS-CoV-2 with combinatorial AAV/RNAi expression vectors. <i>Molecular Therapy</i> , 2022, 30, 2005-2023.	3.7	10
561	Genomic surveillance of SARS-CoV-2 Spike gene by sanger sequencing. <i>PLoS ONE</i> , 2022, 17, e0262170.	1.1	15
562	Prolonged Shedding of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at High Viral Loads Among Hospitalized Immunocompromised Persons Living With Human Immunodeficiency Virus (HIV), South Africa. <i>Clinical Infectious Diseases</i> , 2022, 75, e144-e156.	2.9	32
563	Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 72.	2.1	13
564	Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice. <i>International Journal of Antimicrobial Agents</i> , 2022, 59, 106499.	1.1	15
565	Emergence of a novel SARS-CoV-2 Pango lineage B.1.1.526 in West Bengal, India. <i>Journal of Infection and Public Health</i> , 2022, 15, 42-50.	1.9	3
566	Genomic characterization of the dominating Beta, V2 variant carrying vaccinated (Oxford~AstraZeneca) and nonvaccinated COVID-19 patient samples in Bangladesh: A metagenomics and whole-genome approach. <i>Journal of Medical Virology</i> , 2022, 94, 1670-1688.	2.5	6
568	Investigating vaccine-induced immunity and its effect in mitigating SARS-CoV-2 epidemics in China. <i>BMC Medicine</i> , 2022, 20, 37.	2.3	10
569	Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants. <i>Frontiers in Medicine</i> , 2021, 8, 836826.	1.2	15
570	The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines. <i>Frontiers in Medicine</i> , 2021, 8, 806641.	1.2	22
571	SARS-COV-2 Variants: Differences and Potential of Immune Evasion. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 781429.	1.8	154

#	ARTICLE	IF	CITATIONS
572	USP10 regulates B cell response to SARS-CoV-2 or HIV-1 nanoparticle vaccines through deubiquitinating AID. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 7.	7.1	9
573	Antidepressant and Antipsychotic Drugs Reduce Viral Infection by SARS-CoV-2 and Fluoxetine Shows Antiviral Activity Against the Novel Variants in vitro. <i>Frontiers in Pharmacology</i> , 2021, 12, 755600.	1.6	34
574	Are convalescent plasma stocks collected during former COVID-19 waves still effective against current SARS-CoV-2 variants?. <i>Vox Sanguinis</i> , 2022, 117, 641-646.	0.7	8
575	R346K Mutation in the μ Variant of SARS-CoV-2 Alters the Interactions with Monoclonal Antibodies from Class 2: A Free Energy Perturbation Study. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 627-631.	2.5	25
576	Predicting spike protein NTD mutations of SARS-CoV-2 causing immune evasion by molecular dynamics simulations. <i>Physical Chemistry Chemical Physics</i> , 2022, 24, 3410-3419.	1.3	2
577	SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. <i>Cell Host and Microbe</i> , 2022, 30, 154-162.e5.	5.1	153
578	Engineered small extracellular vesicles displaying ACE2 variants on the surface protect against SARS-CoV-2 infection. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12179.	5.5	24
579	Growth, Antigenicity, and Immunogenicity of SARS-CoV-2 Spike Variants Revealed by a Live rVSV-SARS-CoV-2 Virus. <i>Frontiers in Medicine</i> , 2021, 8, 793437.	1.2	4
580	Regional and temporal coordinated mutation patterns in SARS-CoV-2 spike protein revealed by a clustering and network analysis. <i>Scientific Reports</i> , 2022, 12, 1128.	1.6	28
581	In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant. <i>Transboundary and Emerging Diseases</i> , 2022, 69, 2649-2655.	1.3	1
582	Limited spread of a rare spike E484K-harboring SARS-CoV-2 in Marseille, France. <i>Archives of Virology</i> , 2022, 167, 583.	0.9	3
583	Persistence of functional memory B cells recognizing SARS-CoV-2 variants despite loss of specific IgG. <i>IScience</i> , 2022, 25, 103659.	1.9	16
584	Insight into COVID-19's epidemiology, pathology, and treatment. <i>Heliyon</i> , 2022, 8, e08799.	1.4	19
585	Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants. <i>Viruses</i> , 2022, 14, 230.	1.5	1
586	Analisis Efikasi dan Efektivitas Vaksin COVID-19 terhadap Varian SARS-CoV-2: Sebuah Tinjauan Literatur. <i>Jurnal Kedokteran Meditek</i> , 2022, 28, 107-119.	0.1	0
587	An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. <i>Nature Medicine</i> , 2022, 28, 490-495.	15.2	577
588	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	55
589	CoVax501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity. <i>Cell Discovery</i> , 2022, 8, 9.	3.1	12

#	ARTICLE	IF	CITATIONS
590	Bovine-derived antibodies and camelid-derived nanobodies as biotherapeutic weapons against SARS-CoV-2 and its variants: A review article. <i>International Journal of Surgery</i> , 2022, 98, 106233.	1.1	21
591	Increased Antibody Avidity and Cross-Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Variants by Hyperimmunized Transchromosomal Bovine-Derived Human Immunoglobulins for Treatment of Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2022, 226, 655-663.	1.9	4
592	SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations. <i>Infection and Drug Resistance</i> , 2022, Volume 15, 373-385.	1.1	24
593	Immune response to SARS-CoV-2 variants: A focus on severity, susceptibility, and preexisting immunity. <i>Journal of Infection and Public Health</i> , 2022, 15, 277-288.	1.9	21
594	Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	15
595	Bacteria-enabled oral delivery of a replicon-based mRNA vaccine candidate protects against ancestral and delta variant SARS-CoV-2. <i>Molecular Therapy</i> , 2022, 30, 1926-1940.	3.7	16
596	Coinfection with SARS-CoV-2 and Influenza A Virus Increases Disease Severity and Impairs Neutralizing Antibody and CD4 ⁺ T Cell Responses. <i>Journal of Virology</i> , 2022, 96, jvi0187321.	1.5	38
597	The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges. <i>Journal of Infection and Public Health</i> , 2022, 15, 228-240.	1.9	122
598	Recurrent COVID-19 Polymerase Chain Reaction (PCR) Positivity in 2 Patients During the Current Health Care System Crisis. <i>American Journal of Case Reports</i> , 2022, 23, e935414.	0.3	1
599	501Y.V2 spike protein resists the neutralizing antibody in atomistic simulations. <i>Computational Biology and Chemistry</i> , 2022, 97, 107636.	1.1	1
600	Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria. <i>Nature Communications</i> , 2022, 13, 688.	5.8	23
602	Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. <i>Nature Microbiology</i> , 2022, 7, 423-433.	5.9	78
603	Introduction of the SARS-CoV-2 Beta variant from Comoros into the Marseille geographical area. <i>Travel Medicine and Infectious Disease</i> , 2022, 46, 102277.	1.5	3
604	Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults. <i>Lancet Microbe</i> , The, 2022, 3, e173-e183.	3.4	31
605	A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection. <i>Science Translational Medicine</i> , 2022, 14, eabi9215.	5.8	123
606	The Complexity of SARS-CoV-2 Infection and the COVID-19 Pandemic. <i>Frontiers in Microbiology</i> , 2022, 13, 789882.	1.5	20
607	Rapid detection of multiple SARS-CoV-2 variants of concern by PAM-targeting mutations. <i>Cell Reports Methods</i> , 2022, 2, 100173.	1.4	12
608	Ad26.COVS.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern. <i>Cell Reports Medicine</i> , 2022, 3, 100535.	3.3	31

#	ARTICLE	IF	CITATIONS
609	Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	77
610	Are There Hidden Genes in DNA/RNA Vaccines?. <i>Frontiers in Immunology</i> , 2022, 13, 801915.	2.2	9
613	Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19i/4ša meta-analysis. <i>Annals of Medicine</i> , 2022, 54, 516-523.	1.5	290
614	Epidemiology and genetic diversity of SARS-CoV-2 lineages circulating in Africa. <i>IScience</i> , 2022, 25, 103880.	1.9	6
615	A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. <i>PLoS Pathogens</i> , 2022, 18, e1010248.	2.1	48
616	Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications. <i>Current Microbiology</i> , 2022, 79, 20.	1.0	48
617	SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. <i>Cell Reports</i> , 2021, 37, 110143.	2.9	94
618	Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding. <i>Cell Reports</i> , 2021, 37, 110156.	2.9	67
619	Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex. <i>EBioMedicine</i> , 2021, 74, 103748.	2.7	17
620	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. <i>Nature</i> , 0, , .	13.7	104
621	The emergence, genomic diversity and global spread of SARS-CoV-2. <i>Nature</i> , 2021, 600, 408-418.	13.7	249
622	Enhanced fitness of SARS-CoV-2 variant of concern Alpha but not Beta. <i>Nature</i> , 2022, 602, 307-313.	13.7	79
623	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. <i>Nature</i> , 2022, 602, 654-656.	13.7	928
624	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)â€™Specific Memory B Cells From Individuals With Diverse Disease Severities Recognize SARS-CoV-2 Variants of Concern. <i>Journal of Infectious Diseases</i> , 2022, 225, 947-956.	1.9	13
629	Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. <i>Science</i> , 2021, 374, 1621-1626.	6.0	232
631	Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. <i>ELife</i> , 2021, 10, .	2.8	36
632	Why are some coronavirus variants more infectious?. <i>Journal of Biosciences</i> , 2021, 46, .	0.5	2
633	Vaccine efficacy in mutant SARS-CoV-2 variants. , 2021, 4, 1-12.		4

#	ARTICLE	IF	CITATIONS
634	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. <i>Science Translational Medicine</i> , 2021, , eabm3302.	5.8	13
635	Evolutionary history of the SARS-CoV-2 Gamma variant of concern (P.1): a perfect storm. <i>Genetics and Molecular Biology</i> , 2022, 45, e20210309.	0.6	8
636	Inhibitor screening using microarray identifies the high capacity of neutralizing antibodies to Spike variants in SARS-CoV-2 infection and vaccination. <i>Theranostics</i> , 2022, 12, 2519-2534.	4.6	3
637	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants. <i>Pathogens</i> , 2022, 11, 275.	1.2	9
638	COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity. <i>Journal of Microbiology</i> , 2022, 60, 321-334.	1.3	12
640	Assessment of Mutations Associated With Genomic Variants of SARS-CoV-2: RT-qPCR as a Rapid and Affordable Tool to Monitoring Known Circulating Variants in Chile, 2021. <i>Frontiers in Medicine</i> , 2022, 9, 841073.	1.2	2
641	Memory B Cells Induced by Sputnik V Vaccination Produce SARS-CoV-2 Neutralizing Antibodies Upon Ex Vivo Restimulation. <i>Frontiers in Immunology</i> , 2022, 13, 840707.	2.2	11
642	Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay. <i>Communications Biology</i> , 2022, 5, 169.	2.0	118
643	Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). <i>Scientific Reports</i> , 2022, 12, 2552.	1.6	23
644	Real-Time RT-PCR Allelic Discrimination Assay for Detection of N501Y Mutation in the Spike Protein of SARS-CoV-2 Associated with B.1.1.7 Variant of Concern. <i>Microbiology Spectrum</i> , 2022, 10, e0068121.	1.2	5
646	Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants. <i>PLoS Pathogens</i> , 2022, 18, e1010260.	2.1	81
647	Evolutionary dynamics of the severe acute respiratory syndrome coronavirus 2 genomes. <i>Medical Review</i> , 2022, 2, 3-22.	0.3	7
648	Early Genomic, Epidemiological, and Clinical Description of the SARS-CoV-2 Omicron Variant in Mexico City. <i>Viruses</i> , 2022, 14, 545.	1.5	23
649	Multivariate mining of an alpaca immune repertoire identifies potent cross-neutralizing SARS-CoV-2 nanobodies. <i>Science Advances</i> , 2022, 8, eabm0220.	4.7	18
650	A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant. <i>Vaccines</i> , 2022, 10, 508.	2.1	5
651	Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy. <i>Medical Microbiology and Immunology</i> , 2022, 211, 79-103.	2.6	9
652	Identifying SARS-CoV-2 Lineage Mutation Hallmarks and Correlating Them With Clinical Outcomes in Egypt: A Pilot Study. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 817735.	1.6	1
653	Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting. <i>Cell Reports</i> , 2022, 38, 110561.	2.9	16

#	ARTICLE	IF	CITATIONS
654	Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates. <i>Nature Communications</i> , 2022, 13, 1699.	5.8	34
655	VSV-Based Vaccines Reduce Virus Shedding and Viral Load in Hamsters Infected with SARS-CoV-2 Variants of Concern. <i>Vaccines</i> , 2022, 10, 435.	2.1	8
658	Immunogenicity of the Xcl1-SARS-CoV-2 Spike Fusion DNA Vaccine for COVID-19. <i>Vaccines</i> , 2022, 10, 407.	2.1	5
659	SARS-CoV-2 mRNA vaccine induced higher antibody affinity and IgG titers against variants of concern in post-partum vs non-post-partum women. <i>EBioMedicine</i> , 2022, 77, 103940.	2.7	3
662	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. <i>MBio</i> , 2022, 13, e0297921.	1.8	117
663	Structural basis of nanobodies neutralizing SARS-CoV-2 variants. <i>Structure</i> , 2022, 30, 707-720.e5.	1.6	11
664	Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study. <i>Lancet Infectious Diseases</i> , 2022, 22, 813-820.	4.6	64
665	AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2. <i>BMC Medicine</i> , 2022, 20, 128.	2.3	17
666	Antigen-antibody Complex-Guided Exploration of the Hotspots Conferring the Immune-Escaping Ability of the SARS-CoV-2 RBD. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 797132.	1.6	3
667	Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. <i>Science</i> , 2022, 376, eabn4947.	6.0	651
668	Protective Immunity of the Primary SARS-CoV-2 Infection Reduces Disease Severity Post Re-Infection with Delta Variants in Syrian Hamsters. <i>Viruses</i> , 2022, 14, 596.	1.5	6
669	Inhibition of Respiratory RNA Viruses by a Composition of Ionophoric Polyphenols with Metal Ions. <i>Pharmaceuticals</i> , 2022, 15, 377.	1.7	7
670	Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. <i>Science</i> , 2022, 376, eabn8897.	6.0	119
671	Analysis of accumulated SARS-CoV-2 seroconversion in North Carolina: The COVID-19 Community Research Partnership. <i>PLoS ONE</i> , 2022, 17, e0260574.	1.1	3
672	SARS-CoV-2 spike E156G/I ¹⁵⁷⁻¹⁵⁸ mutations contribute to increased infectivity and immune escape. <i>Life Science Alliance</i> , 2022, 5, e202201415.	1.3	24
673	Human placenta-derived amniotic epithelial cells as a new therapeutic hope for COVID-19-associated acute respiratory distress syndrome (ARDS) and systemic inflammation. <i>Stem Cell Research and Therapy</i> , 2022, 13, 126.	2.4	15
674	COVID-19 Outbreaks in Nursing Homes Despite Full Vaccination with BNT162b2 of a Majority of Residents. <i>Gerontology</i> , 2022, 68, 1384-1392.	1.4	9
675	Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models. <i>Journal of Microbiology</i> , 2022, 60, 255-267.	1.3	9

#	ARTICLE	IF	CITATIONS
676	A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	49
677	Injectable Slow-Release Hydrogel Formulation of a Plant Virus-Based COVID-19 Vaccine Candidate. <i>Biomacromolecules</i> , 2022, 23, 1812-1825.	2.6	20
678	SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals. <i>Cell Host and Microbe</i> , 2022, 30, 880-886.e4.	5.1	80
679	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. <i>EBioMedicine</i> , 2022, 77, 103902.	2.7	23
680	Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus 2 After the Second Wave in South Africa in Human Immunodeficiency Virus-Infected and Uninfected Persons: A Cross-Sectional Household Survey. <i>Clinical Infectious Diseases</i> , 2022, 75, e57-e68.	2.9	11
681	Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?. <i>Drug Design, Development and Therapy</i> , 2022, Volume 16, 951-972.	2.0	4
682	Structural conservation among variants of the SARS-CoV-2 spike postfusion bundle. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2119467119.	3.3	25
683	COVID-19 vaccines: their effectiveness against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging variants. <i>Bulletin of the National Research Centre</i> , 2022, 46, 96.	0.7	25
686	Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2022, 13, 1788.	5.8	30
687	Spike protein of SARS-CoV-2 variants: a brief review and practical implications. <i>Brazilian Journal of Microbiology</i> , 2022, 53, 1133-1157.	0.8	22
688	Emergence, evolution, and vaccine production approaches of SARS-CoV-2 virus: Benefits of getting vaccinated and common questions. <i>Saudi Journal of Biological Sciences</i> , 2022, 29, 1981-1997.	1.8	5
689	Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates. <i>Vaccine</i> , 2022, 40, 2960-2969.	1.7	5
690	Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage. <i>Nature Communications</i> , 2022, 13, 1976.	5.8	27
691	RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 104043.	1.9	19
692	Dynamic Ca ²⁺ sensitivity stimulates the evolved SARS-CoV-2 spike strain-mediated membrane fusion for enhanced entry. <i>Cell Reports</i> , 2022, 39, 110694.	2.9	19
693	Liushen Capsules, a promising clinical candidate for COVID-19, alleviates SARS-CoV-2-induced pulmonary in vivo and inhibits the proliferation of the variant virus strains in vitro. <i>Chinese Medicine</i> , 2022, 17, 40.	1.6	8
694	Fast detection of SARS-CoV-2 variants including Omicron using one-step RT-PCR and Sanger sequencing. <i>Journal of Virological Methods</i> , 2022, 304, 114512.	1.0	18
695	Neutralizing Antibodies and Cytokines in Breast Milk After Coronavirus Disease 2019 (COVID-19) mRNA Vaccination. <i>Obstetrics and Gynecology</i> , 2022, 139, 181-191.	1.2	44

#	ARTICLE	IF	CITATIONS
696	Molecular and Clinical Aspects of COVID-19 Vaccines and Other Therapeutic Interventions Apropos Emerging Variants of Concern. <i>Frontiers in Pharmacology</i> , 2021, 12, 778219.	1.6	0
701	Identification of HLA-A*24:02-Restricted CTL Candidate Epitopes Derived from the Nonstructural Polyprotein 1a of SARS-CoV-2 and Analysis of Their Conservation Using the Mutation Database of SARS-CoV-2 Variants. <i>Microbiology Spectrum</i> , 2021, 9, e0165921.	1.2	2
702	Impact of SARS-CoV-2 variants of concern on Covid-19 epidemic in South Africa. <i>Transactions of the Royal Society of South Africa</i> , 0, , 1-4.	0.8	2
703	A Stabilized, Monomeric, Receptor Binding Domain Elicits High-Titer Neutralizing Antibodies Against All SARS-CoV-2 Variants of Concern. <i>Frontiers in Immunology</i> , 2021, 12, 765211.	2.2	16
704	Propagation of SARS-CoV-2 in Calu-3 Cells to Eliminate Mutations in the Furin Cleavage Site of Spike. <i>Viruses</i> , 2021, 13, 2434.	1.5	19
705	The Development of SARS-CoV-2 Variants: The Gene Makes the Disease. <i>Journal of Developmental Biology</i> , 2021, 9, 58.	0.9	27
707	An update on host immunity correlates and prospects of re-infection in COVID-19. <i>International Reviews of Immunology</i> , 2022, 41, 367-392.	1.5	9
708	Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13202.	1.8	20
709	Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 795741.	2.2	13
710	Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Ad26.CoV2.S Vaccination in People Living With Human Immunodeficiency Virus (HIV). <i>Clinical Infectious Diseases</i> , 2022, 75, e857-e864.	2.9	30
711	Estimating the strength of selection for new SARS-CoV-2 variants. <i>Nature Communications</i> , 2021, 12, 7239.	5.8	23
712	Convalescent plasma for COVID-19: Donor demographic factors associated high neutralising antibody titres. <i>Transfusion Medicine</i> , 2022, 32, 327-337.	0.5	5
713	ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants. <i>Cell Reports</i> , 2022, 39, 110757.	2.9	10
714	DeepSARS: simultaneous diagnostic detection and genomic surveillance of SARS-CoV-2. <i>BMC Genomics</i> , 2022, 23, 289.	1.2	5
716	Impact of SARS-CoV-2 Gamma lineage introduction and COVID-19 vaccination on the epidemiological landscape of a Brazilian city. <i>Communications Medicine</i> , 2022, 2, .	1.9	32
717	Development of antibody resistance in emerging mutant strains of SARS CoV-2: Impediment for COVID-19 vaccines. <i>Reviews in Medical Virology</i> , 2022, 32, e2346.	3.9	16
718	Clinical Characteristics, Transmissibility, Pathogenicity, Susceptible Populations, and Re-infectivity of Prominent COVID-19 Variants. , 2022, 13, 402.		28
719	SARS-CoV-2 Variants of Concern Increased Transmission and Decrease Vaccine Efficacy in the COVID-19 Pandemic in Palembang Indonesia.. <i>Acta Biomedica</i> , 2022, 93, e2022018.	0.2	0

#	ARTICLE	IF	CITATIONS
720	Escape from recognition of SARS-CoV-2 Beta variant spike epitopes but overall preservation of T cell immunity.. <i>Science Translational Medicine</i> , 2021, , eabj6824.	5.8	11
721	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24
722	Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants. <i>BioDrugs</i> , 2022, 36, 231-323.	2.2	24
723	Developing Small-Molecule Inhibitors of Protein-Protein Interactions Involved in Viral Entry as Potential Antivirals for COVID-19. <i>Frontiers in Drug Discovery</i> , 2022, 2, .	1.1	5
724	SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance. <i>Frontiers in Immunology</i> , 2022, 13, 877101.	2.2	74
725	Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. <i>Cell</i> , 2022, 185, 2265-2278.e14.	13.5	77
726	Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 2068883.	1.4	44
727	Combining genomic and epidemiological data to compare the transmissibility of SARS-CoV-2 variants Alpha and Iota. <i>Communications Biology</i> , 2022, 5, 439.	2.0	9
728	Convergent Evolution of Multiple Mutations Improves the Viral Fitness of SARS-CoV-2 Variants by Balancing Positive and Negative Selection. <i>Biochemistry</i> , 2022, 61, 963-980.	1.2	12
729	Whole genome sequencing of SARS-CoV2 strains circulating in Iran during five waves of pandemic. <i>PLoS ONE</i> , 2022, 17, e0267847.	1.1	20
730	Discovery of adapalene and dihydrotachysterol as antiviral agents for the Omicron variant of SARS-CoV-2 through computational drug repurposing. <i>Molecular Diversity</i> , 2023, 27, 463-475.	2.1	25
731	Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host. <i>Nature Communications</i> , 2022, 13, 2560.	5.8	64
732	Fitness of B-Cell Responses to SARS-CoV-2 WT and Variants Up to One Year After Mild COVID-19 – A Comprehensive Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 841009.	2.2	0
733	Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques. <i>Molecular Therapy</i> , 2022, 30, 2952-2967.	3.7	2
734	Human-to-dog transmission of SARS-CoV-2, Colombia. <i>Scientific Reports</i> , 2022, 12, 7880.	1.6	9
735	Physicochemical effect of the N501Y, E484K/Q, K417N/T, L452R and T478K mutations on the SARS-CoV-2 spike protein RBD and its influence on agent fitness and on attributes developed by emerging variants of concern. <i>Virology</i> , 2022, 572, 44-54.	1.1	21
736	Understanding the omicron variant (B.1.1.529) of SARS-CoV-2: Mutational impacts, concerns, and the possible solutions. <i>Annals of Medicine and Surgery</i> , 2022, 78, 103737.	0.5	33
737	Design, immunogenicity, and efficacy of a pan-sarbecovirus dendritic-cell targeting vaccine. <i>EBioMedicine</i> , 2022, 80, 104062.	2.7	10

#	ARTICLE	IF	CITATIONS
738	Safety & effectiveness of COVID-19 vaccines: A narrative review. <i>Indian Journal of Medical Research</i> , 2022, 155, 91.	0.4	22
740	Modeling Infectious Behaviors: The Need to Account for Behavioral Adaptation in COVID-19 Models.. <i>Journal on Policy and Complex Systems</i> , 2021, 7, 21-32.	0.1	0
743	Role of COVID-19 Vaccines in SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	37
744	The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Concern. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	43
745	Protective effect of a first SARS-CoV-2 infection from reinfection: a matched retrospective cohort study using PCR testing data in England. <i>Epidemiology and Infection</i> , 2022, 150, .	1.0	8
746	Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein. <i>Cell</i> , 2022, 185, 2279-2291.e17.	13.5	25
747	VH3-53/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages. <i>Journal of Personalized Medicine</i> , 2022, 12, 895.	1.1	2
748	A conserved subunit vaccine designed against SARS-CoV-2 variants showed evidence in neutralizing the virus. <i>Applied Microbiology and Biotechnology</i> , 2022, 106, 4091-4114.	1.7	6
749	Leveraging on past investment in understanding the immunology of COVID-19 – the South African experience. <i>South African Journal of Science</i> , 2022, 118, .	0.3	1
750	Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 1207-1221.	1.2	3
751	Leveraging South African HIV research to define SARS-CoV-2 immunity triggered by sequential variants of concern. <i>Immunological Reviews</i> , 2022, 310, 61-75.	2.8	6
752	Prognosis of patients with acute respiratory failure due to the SARS-CoV-2 501Y.V2 variant: a multicenter retrospective matched cohort study. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
753	An early warning system for emerging SARS-CoV-2 variants. <i>Nature Medicine</i> , 2022, 28, 1110-1115.	15.2	47
754	Real-World Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	25
755	A random priming amplification method for whole genome sequencing of SARS-CoV-2 virus. <i>BMC Genomics</i> , 2022, 23, .	1.2	6
756	Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis. <i>Lancet Microbe</i> , The, 2022, 3, e493-e502.	3.4	22
757	SARS-CoV-2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice. <i>Small</i> , 2022, 18, .	5.2	11
758	Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. <i>Nature Immunology</i> , 2022, 23, 960-970.	7.0	39

#	ARTICLE	IF	CITATIONS
759	Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection. <i>Emerging Microbes and Infections</i> , 2022, 11, 1500-1507.	3.0	1
760	An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant replication in rhesus macaques. , 2022, 1, .		10
761	Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants. <i>Viruses</i> , 2022, 14, 1332.	1.5	12
762	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. <i>Vaccines</i> , 2022, 10, 919.	2.1	23
763	Synergistic interactions of repurposed drugs that inhibit Nsp1, a major virulence factor for COVID-19. <i>Scientific Reports</i> , 2022, 12, .	1.6	9
764	Depending on Epitope Profile of COVID-19 mRNA Vaccine Recipients: Are They More Efficient Against the Arising Viral Variants? An Opinion Article. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
765	Synergistic Antiviral Activity of Pamapimod and Pioglitazone against SARS-CoV-2 and Its Variants of Concern. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6830.	1.8	5
766	Potent human broadly SARS-CoV-2 neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	34
768	Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2. <i>Transfusion Medicine Reviews</i> , 2022, 36, 125-132.	0.9	8
769	An updated review of <sc>SARS-CoV-2</sc> detection methods in the context of a novel coronavirus pandemic. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	19
771	Automated Library Construction and Analysis for High-throughput Nanopore Sequencing of SARS-CoV-2. <i>journal of applied laboratory medicine</i> , The, 0, , .	0.6	0
772	Microbiome Analysis for Wastewater Surveillance during COVID-19. <i>MBio</i> , 2022, 13, .	1.8	40
773	Structural basis of Omicron immune evasion: A comparative computational study. <i>Computers in Biology and Medicine</i> , 2022, 147, 105758.	3.9	6
775	Inhibitors of Deubiquitinating Enzymes Interfere with the SARS-CoV-2 Papain-like Protease and Block Virus Replication In Vitro. <i>Viruses</i> , 2022, 14, 1404.	1.5	7
776	The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes. <i>PLoS Pathogens</i> , 2022, 18, e1010592.	2.1	13
777	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	28
778	Will Peptides Help to Stop COVID-19?. <i>Biochemistry (Moscow)</i> , 2022, 87, 590-604.	0.7	1
781	Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7675.	1.8	9

#	ARTICLE	IF	CITATIONS
782	A review of mass spectrometry-based analyses to understand COVID-19 convalescent plasma mechanisms of action. <i>Proteomics</i> , 0, , 2200118.	1.3	3
783	Two Years of Evolutionary Dynamics of SARS-CoV-2 in Mexico, With Emphasis on the Variants of Concern. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	3
784	Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 5707-5727.	2.0	7
785	COVID-19: Challenges of Viral Variants. <i>Annual Review of Medicine</i> , 2023, 74, 31-53.	5.0	43
786	Early detection and surveillance of SARS-CoV-2 genomic variants in wastewater using COJAC. <i>Nature Microbiology</i> , 2022, 7, 1151-1160.	5.9	69
787	What, Where, When and How of COVID-19 Patents Landscape: A Bibliometrics Review. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
788	Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	6
789	Host-Genome Similarity Characterizes the Adaption of SARS-CoV-2 to Humans. <i>Biomolecules</i> , 2022, 12, 972.	1.8	1
790	Novel Lateral Flow-Based Assay for Simple and Visual Detection of SARS-CoV-2 Mutations. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	1
791	Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants. <i>Journal of Virology</i> , 2022, 96, .	1.5	7
792	Comparison of viral propagation and drug response among SARS-CoV-2 VOCs using replicons capable of recapitulating virion assembly and release. <i>Virologica Sinica</i> , 2022, 37, 695-703.	1.2	1
794	Unsuppressed HIV infection impairs T cell responses to SARS-CoV-2 infection and abrogates T cell cross-recognition. <i>ELife</i> , 0, 11, .	2.8	12
795	Interferon resistance of emerging SARS-CoV-2 variants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	63
796	Potent and Broad Neutralization of SARS-CoV-2 Variants of Concern (VOCs) including Omicron Sub-lineages BA.1 and BA.2 by Biparatopic Human VH Domains. <i>IScience</i> , 2022, , 104798.	1.9	1
798	Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review. <i>International Journal of Biological Sciences</i> , 2022, 18, 4629-4641.	2.6	24
799	Perspective Chapter: Bioinformatics Study of the Evolution of SARS-CoV-2 Spike Protein. <i>Infectious Diseases</i> , 0, , .	4.0	0
800	SARS-CoV-2 S2a-targeted vaccination elicits broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	57
801	Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3

#	ARTICLE	IF	CITATIONS
802	Immune Escape Associated with RBD Omicron Mutations and SARS-CoV-2 Evolution Dynamics. <i>Viruses</i> , 2022, 14, 1603.	1.5	27
804	Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 From Adult Index Cases With and Without Human Immunodeficiency Virus in South Africa, 2020â€“2021: A Case-Ascertained, Prospective, Observational Household Transmission Study. <i>Clinical Infectious Diseases</i> , 2023, 76, e71-e81.	2.9	6
805	Virtual screening reveals liquiritigenin as a broad-spectrum inhibitor of SARS-CoV-2 variants of concern: an <i>in silico</i> study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 6709-6727.	2.0	2
806	COVID-19 and pregnancy: clinical outcomes; mechanisms, and vaccine efficacy. <i>Translational Research</i> , 2023, 251, 84-95.	2.2	14
807	Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways. <i>IScience</i> , 2022, 25, 104914.	1.9	5
808	SARS-CoV-2 RBD-Specific Antibodies Induced Early in the Pandemic by Natural Infection and Vaccination Display Cross-Variant Binding and Inhibition. <i>Viruses</i> , 2022, 14, 1861.	1.5	4
809	A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern. <i>Journal of Virology</i> , 2022, 96, .	1.5	14
810	Association Between Human Immunodeficiency Virus Viremia and Compromised Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Beta Variant. <i>Journal of Infectious Diseases</i> , 2023, 227, 211-220.	1.9	6
811	Homologous or Heterologous COVID-19 Booster Regimens Significantly Impact Sero-Neutralization of SARS-CoV-2 Virus and Its Variants. <i>Vaccines</i> , 2022, 10, 1321.	2.1	4
812	Characterization of a broadly cross reactive tetraivalent human monoclonal antibody, recognizing conformational epitopes in receptor binding domain of SARS-CoV-2. <i>3 Biotech</i> , 2022, 12, .	1.1	2
813	Lessons from SARS-CoV, MERS-CoV, and SARS-CoV-2 Infections: What We Know So Far. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-13.	0.7	5
814	Humoral responses to the SARS-CoV-2 spike and receptor binding domain in context of pre-existing immunity confer broad sarbecovirus neutralization. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
815	Molecular Dynamics Analysis of Fast-Spreading Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Their Effects on the Interaction with Human Angiotensin-Converting Enzyme 2. <i>ACS Omega</i> , 2022, 7, 30700-30709.	1.6	6
816	Epitopes mapped onto SARS-CoV-2 receptor-binding motif by five distinct human neutralising antibodies. <i>Molecular Simulation</i> , 0, , 1-11.	0.9	0
817	Modeling SARS-CoV-2 and influenza infections and antiviral treatments in human lung epithelial tissue equivalents. <i>Communications Biology</i> , 2022, 5, .	2.0	11
818	Design and Immunoinformatic Assessment of Candidate Multivariant mRNA Vaccine Construct against Immune Escape Variants of SARS-CoV-2. <i>Polymers</i> , 2022, 14, 3263.	2.0	3
819	Efficacy and safety of COVIDâ€“19 vaccines: A network metaâ€“analysis. <i>Journal of Evidence-Based Medicine</i> , 2022, 15, 245-262.	0.7	14
820	Expert consensus on the diagnosis and treatment of severe and critical coronavirus disease 2019 (COVID-19). <i>Journal of Intensive Medicine</i> , 2022, 2, 199-222.	0.8	3

#	ARTICLE	IF	CITATIONS
821	Monitoring of Both Humoral and Cellular Immunities Could Early Predict COVID-19 Vaccine Efficacy Against the Different SARS-CoV2 Variants. <i>Journal of Clinical Immunology</i> , 2023, 43, 31-45.	2.0	4
823	Genomic surveillance, evolution and global transmission of SARS-CoV-2 during 2019â€“2022. <i>PLoS ONE</i> , 2022, 17, e0271074.	1.1	14
824	Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	15
825	Passive immunization with equine RBD-specific Fab protects K18-hACE2-mice against Alpha or Beta variants of SARS-CoV-2. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
826	Temporal lineage replacements and dominance of imported variants of concern during the COVID-19 pandemic in Kenya. <i>Communications Medicine</i> , 2022, 2, .	1.9	4
827	Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination. <i>International Immunopharmacology</i> , 2022, 111, 109128.	1.7	9
828	Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113522.	2.5	56
829	From Alpha to Omicron BA.2: New digital RT-PCR approach and challenges for SARS-CoV-2 VOC monitoring and normalization of variant dynamics in wastewater. <i>Science of the Total Environment</i> , 2022, 848, 157740.	3.9	13
830	State-of-art high-performance Nano-systems for mutated coronavirus infection management: From Lab to Clinic. <i>OpenNano</i> , 2022, 8, 100078.	1.8	11
831	Learnings from the Australian first few X household transmission project for COVID-19. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 28, 100573.	1.3	3
832	Mathematical artificial intelligence design of mutation-proof COVID-19 monoclonal antibodies. <i>Communications in Information and Systems</i> , 2022, 22, 339-361.	0.3	2
833	SARS-CoV-2 Variants: Impact of Spike Mutations on Vaccine and Therapeutic Strategies. , 2022, , 143-160.		0
834	Genetics and Biological Characteristics of SARS-CoV-2. , 2022, , 49-66.		0
835	Durability of ChAdOx1 nCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity Against Variants Including Omicron BA.1 and BA.4 Six Months after Vaccination: A Randomised, Phase 1b/2a Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
836	Antibody-mediated immunity to SARS-CoV-2 spike. <i>Advances in Immunology</i> , 2022, , 1-69.	1.1	12
837	SARSâ€“CoVâ€“2 does not infect pigs, but this has to be verified regularly. <i>Xenotransplantation</i> , 2022, 29, .	1.6	3
838	Potential Therapeutic Role of Mesenchymal-Derived Stem Cells as an Alternative Therapy to Combat COVID-19 through Cytokines Storm. <i>Cells</i> , 2022, 11, 2686.	1.8	1
839	Broad-Spectrum Small-Molecule Inhibitors of the SARS-CoV-2 Spikeâ€“ACE2 Proteinâ€“Protein Interaction from a Chemical Space of Privileged Protein Binders. <i>Pharmaceuticals</i> , 2022, 15, 1084.	1.7	5

#	ARTICLE	IF	CITATIONS
840	Deep mutational learning predicts ACE2 binding and antibody escape to combinatorial mutations in the SARS-CoV-2 receptor-binding domain. <i>Cell</i> , 2022, 185, 4008-4022.e14.	13.5	55
841	A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
842	Mutations in SARS-CoV-2 nucleocapsid in variants of concern impair the sensitivity of SARS-CoV-2 detection by rapid antigen tests. <i>Frontiers in Virology</i> , 0, 2, .	0.7	3
844	Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants. <i>Cell Reports</i> , 2022, 41, 111528.	2.9	6
845	Dynamics of Neutralizing Antibodies and Binding Antibodies to Domains of SARS-CoV-2 Spike Protein in COVID-19 Survivors. <i>Viral Immunology</i> , 2022, 35, 545-552.	0.6	4
847	Perspective Chapter: Real-Time Genomic Surveillance for SARS-CoV-2 on Center Stage. <i>Infectious Diseases</i> , 0, , .	4.0	0
848	A Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 1655.	2.1	12
849	Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1bâ€“2a trial. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 295-306.	4.6	14
850	SARS-CoV-2 variants of concern: a review. <i>Monaldi Archives for Chest Disease</i> , 0, , .	0.3	4
851	Etiology and Epidemiology of Croup before and throughout the COVID-19 Pandemic, 2018â€“2022, South Korea. <i>Children</i> , 2022, 9, 1542.	0.6	2
852	HIV skews the SARS-CoV-2 B cell response towards an extrafollicular maturation pathway. <i>ELife</i> , 0, 11, .	2.8	6
853	Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history. <i>Cell Host and Microbe</i> , 2022, 30, 1745-1758.e7.	5.1	31
854	Proteins from Thermophilic <i>Thermus thermophilus</i> Often Do Not Fold Correctly in a Mesophilic Expression System Such as <i>Escherichia coli</i> . <i>ACS Omega</i> , 2022, 7, 37797-37806.	1.6	2
856	Versatile live-attenuated SARS-CoV-2 vaccine platform applicable to variants induces protective immunity. <i>IScience</i> , 2022, 25, 105412.	1.9	8
857	Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions. <i>Biomedicine and Pharmacotherapy</i> , 2023, 157, 113977.	2.5	66
858	<i>In silico</i> study identifies peptide inhibitors that negate the effect of non-synonymous mutations in major drug targets of SARS-CoV-2 variants. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 9551-9561.	2.0	1
859	Reporting complete heart block in a patient with polyarteritis nodosa after COVIDâ€“19 vaccination. <i>ESC Heart Failure</i> , 2023, 10, 1418-1421.	1.4	6
860	A potent, broadly protective vaccine against SARS-CoV-2 variants of concern. <i>Npj Vaccines</i> , 2022, 7, .	2.9	8

#	ARTICLE	IF	CITATIONS
861	Genome characterization, phylogenomic assessment and spatio-temporal dynamics study of highly mutated BA variants from India. <i>Indian Journal of Medical Microbiology</i> , 2022, , .	0.3	1
862	Mutation and SARS-CoV-2 strain competition under vaccination in a modified SIR model. <i>Chaos, Solitons and Fractals</i> , 2023, 166, 112964.	2.5	4
863	A SARS-CoV-2 neutralizing antibody discovery by single cell sequencing and molecular modeling. <i>Journal of Biomedical Research</i> , 2023, 37, 166.	0.7	1
864	Coronavirus disease 2019: current understanding of its pathophysiology and histopathological findings. <i>Journal of the Arab Society for Medical Research</i> , 2022, 17, 108.	0.0	0
865	SARS-CoV-2 Omicron Variant Genomic Sequences and Their Epidemiological Correlates Regarding the End of the Pandemic: In Silico Analysis. <i>JMIR Bioinformatics and Biotechnology</i> , 0, 4, e42700.	0.4	2
866	Modelling optimal lockdowns with waning immunity. <i>Economic Theory</i> , 2024, 77, 197-234.	0.5	7
867	Serological and Molecular Surveillance for SARS-CoV-2 Infection in Captive Tigers (<i>Panthera tigris</i>), Thailand. <i>Animals</i> , 2022, 12, 3350.	1.0	4
868	Saliva and Plasma Neutralizing Activity Induced by the Administration of a Third bnt162b2 Vaccine Dose. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14341.	1.8	4
869	As the SARS-CoV-2 virus evolves, should Omicron subvariant BA.2 be subjected to quarantine, or should we learn to live with it?. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	5
870	Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. <i>Biochemical Society Transactions</i> , 2022, 50, 1643-1658.	1.6	6
871	Challenges and developments in universal vaccine design against SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2022, 7, .	2.9	25
873	Label-Free Analysis of Binding and Inhibition of SARS-Cov-19 Spike Proteins to ACE2 Receptor with ACE2-Derived Peptides by Surface Plasmon Resonance. <i>ACS Applied Bio Materials</i> , 2023, 6, 182-190.	2.3	1
874	Progress Update on the Epidemiology of COVID-19 Variants and the Assessment Status of Developed Vaccines. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2022, 13, 293-299.	0.2	0
876	Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. <i>Journal of Taibah University Medical Sciences</i> , 2023, 18, 600-638.	0.5	1
877	Antibodies Induced by Homologous or Heterologous Inactivated (CoronaVac/BBIBP-CorV) and Recombinant Protein Subunit Vaccines (ZF2001) Dramatically Enhanced Inhibitory Abilities against B.1.351, B.1.617.2, and B.1.1.529 Variants. <i>Vaccines</i> , 2022, 10, 2110.	2.1	2
878	Evaluation of antibody response to SARS-CoV-2 variants after 2 doses of mRNA COVID-19 vaccine in a correctional facility. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	3
879	The SARS-CoV-2 Delta (B.1.617.2) variant with Spike N501Y mutation in the shadow of Omicron emergence. <i>Heliyon</i> , 2022, , e12650.	1.4	0
880	Epidemiology and Characteristics of SARS-CoV-2 Variants of Concern: The Impacts of the Spike Mutations. <i>Microorganisms</i> , 2023, 11, 30.	1.6	11

#	ARTICLE	IF	CITATIONS
881	Modified DNA vaccine confers improved humoral immune response and effective virus protection against SARS-CoV-2 delta variant. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
882	Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant. <i>Cell Reports Medicine</i> , 2023, 4, 100910.	3.3	5
883	Simultaneous spectrofluorimetric determination of remdesivir and simeprevir in human plasma. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
884	A bivalent subunit vaccine efficiently produced in <i>Pichia pastoris</i> against SARS-CoV-2 and emerging variants. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	2
885	Refocus on Immunogenic Characteristics of Convalescent COVID-19 Challenged by Prototype SARS-CoV-2. <i>Vaccines</i> , 2023, 11, 123.	2.1	3
886	European Black Elderberry Fruit Extract Inhibits Replication of SARS-CoV-2 In Vitro. <i>Nutraceuticals</i> , 2023, 3, 91-106.	0.6	3
887	RBD-Based ELISA and Luminex Predict Anti-SARS-CoV-2 Surrogate-Neutralizing Activity in Two Longitudinal Cohorts of German and Spanish Health Care Workers. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	1
888	A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model. <i>Journal of Virology</i> , 0, , .	1.5	2
889	S Trimer Derived from SARS-CoV-2 B.1.351 and B.1.618 Induced Effective Immune Response against Multiple SARS-CoV-2 Variants. <i>Vaccines</i> , 2023, 11, 193.	2.1	1
890	Functional studies of HLA and its role in SARS-CoV-2: Stimulating T cell response and vaccine development. <i>Life Sciences</i> , 2023, 315, 121374.	2.0	3
891	From Challenges to Opportunities and Open Questions. , 2023, , 87-130.		0
892	Safeguarding Against the Analog of Antimicrobial-Resistance Development. , 2023, , 163-176.		0
893	Scales, Pseudoscales, the Human Factor, and a Way Forward. , 2023, , 177-224.		0
895	Hybrid Immunity to SARS-CoV-2 from Infection and Vaccination—Evidence Synthesis and Implications for New COVID-19 Vaccines. <i>Biomedicines</i> , 2023, 11, 370.	1.4	15
896	Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2. <i>Nature Communications</i> , 2023, 14, .	5.8	8
897	Alpha to Omicron (Variants of Concern): Mutation Journey, Vaccines, and Therapy. <i>Viral Immunology</i> , 0, , .	0.6	1
898	Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape. <i>Nature Communications</i> , 2023, 14, .	5.8	21
899	Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19. <i>Viruses</i> , 2023, 15, 448.	1.5	0

#	ARTICLE	IF	CITATIONS
901	Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypes. <i>Cell Reports</i> , 2023, 42, 112370.	2.9	2
902	Different configurations of SARS-CoV-2 spike protein delivered by integrase-defective lentiviral vectors induce persistent functional immune responses, characterized by distinct immunogenicity profiles. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
903	COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease. <i>Drug Discovery Today</i> , 2023, 28, 103579.	3.2	22
904	Defending against SARS-CoV-2: The T cell perspective. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	20
905	Molecular Evolution of SARS-CoV-2 during the COVID-19 Pandemic. <i>Genes</i> , 2023, 14, 407.	1.0	10
906	Evaluation of possible COVID-19 reinfection in children: A multicenter clinical study. <i>Archives De Pediatrie</i> , 2023, 30, 187-191.	0.4	2
907	A case of reinfection with a different variant of SARS-CoV-2: case report. <i>The Egyptian Journal of Internal Medicine</i> , 2023, 35, .	0.3	1
908	SARS-CoV-2 multi-antigen protein microarray for detailed characterization of antibody responses in COVID-19 patients. <i>PLoS ONE</i> , 2023, 18, e0276829.	1.1	4
909	Protein expression/secretion boost by a novel unique 21-mer cis-regulatory motif (Exin21) via mRNA stabilization. <i>Molecular Therapy</i> , 2023, 31, 1136-1158.	3.7	1
910	The impact of COVID-19 and COVID vaccination on cardiovascular outcomes. <i>European Heart Journal Supplements</i> , 2023, 25, A42-A49.	0.0	10
911	Severe Acute Respiratory Syndrome Coronaviruses-2 (SARS-CoV-2). , 2023, , 1-15.		0
912	Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. <i>Immunity</i> , 2023, 56, 669-686.e7.	6.6	43
913	Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method. <i>Antibody Therapeutics</i> , 2023, 6, 76-86.	1.2	0
914	An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. <i>Heliyon</i> , 2023, 9, e13952.	1.4	28
915	A DNA Vaccine Encoding the Full-Length Spike Protein of Beta Variant (B.1.351) Elicited Broader Cross-Reactive Immune Responses against Other SARS-CoV-2 Variants. <i>Vaccines</i> , 2023, 11, 513.	2.1	5
916	Development of Next Generation Vaccines against SARS-CoV-2 and Variants of Concern. <i>Viruses</i> , 2023, 15, 624.	1.5	4
917	Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits. <i>Vaccine</i> , 2023, 41, 2261-2269.	1.7	4
918	Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants. <i>Nature Communications</i> , 2023, 14, .	5.8	8

#	ARTICLE	IF	CITATIONS
919	Variants of SARS-CoV-2: Influences on the Vaccines™ Effectiveness and Possible Strategies to Overcome Their Consequences. <i>Medicina (Lithuania)</i> , 2023, 59, 507.	0.8	5
920	The antiviral activity of a small molecule drug targeting the NSP1-ribosome complex against Omicron, especially in elderly patients. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 13, .	1.8	3
921	Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. <i>Medicinal Research Reviews</i> , 2023, 43, 932-971.	5.0	7
922	Longer intervals between SARS-CoV-2 infection and mRNA 1273 doses improve the neutralization of different variants of concern. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	1
923	SARS-CoV-2 M ^{pro} Protease Variants of Concern Display Altered Viral Substrate and Cell Host Target Galectin-8 Processing but Retain Sensitivity toward Antivirals. <i>ACS Central Science</i> , 2023, 9, 696-708.	5.3	14
924	Exploring the Potential of Broadly Neutralizing Antibodies for Treating SARS-CoV-2 Variants of Global Concern in 2023: A Comprehensive Clinical Review. <i>Cureus</i> , 2023, , .	0.2	1
926	Anti-COVID-19 Credentials of Chitosan Composites and Derivatives: Future Scope?. <i>Antibiotics</i> , 2023, 12, 665.	1.5	1
927	Comprehensive deep mutational scanning reveals the pH induced stability and binding differences between SARS-CoV-2 spike RBD and human ACE2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 15207-15218.	2.0	1
928	HLA Variation and SARS-CoV-2 Specific Antibody Response. <i>Viruses</i> , 2023, 15, 906.	1.5	4
929	Immunology of COVID-19. , 2024, , 52-71.		0
930	The importance of combining serological testing with RT-PCR assays for efficient detection of COVID-19 and higher diagnostic accuracy. <i>PeerJ</i> , 0, 11, e15024.	0.9	4
931	Phytochemicals of <i>Withania somnifera</i> as a Future Promising Drug against SARS-CoV-2: Pharmacological Role, Molecular Mechanism, Molecular Docking Evaluation, and Efficient Delivery. <i>Microorganisms</i> , 2023, 11, 1000.	1.6	2
965	Severe Acute Respiratory Syndrome Coronaviruses-2 (SARS-CoV-2). , 2023, , 1529-1543.		0
974	Innovation-driven trend shaping COVID-19 vaccine development in China. <i>Frontiers of Medicine</i> , 2023, 17, 1096-1116.	1.5	0
976	Importance of Timely Sequencing, Tracking, and Surveillance of Emergent Variants. , 2024, , 166-193.		0
980	Therapeutic landscape of SARS-CoV-2. , 2024, , 83-99.		0